Compositions and methods for promoting T cell entry into tumors and cancers

JP2023549336A5Inactive Publication Date: 2024-11-13CANCER ADVANCES INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527415
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-06
Filing Date
2021-11-08
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current immunotherapy approaches for gastric cancer have low response rates due to tumor-infiltrating CD8+ lymphocytes and fibrosis in the tumor microenvironment, which impedes the penetration of therapeutic agents and immune cells, and existing chemotherapy drugs are not target-specific.

Method used

The use of a gastrin immunogen conjugated to an immunogenic carrier, such as diphtheria toxoid, to promote the entry of anti-tumor immunotherapy molecules, including CAR-T cells, into gastric tumors, thereby enhancing the immune response and overcoming fibrosis.

Benefits of technology

This approach increases the infiltration of CD8+ T cells into tumors, reduces fibrosis, and enhances the effectiveness of immunotherapy, leading to improved survival rates in gastric cancer patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided are methods for promoting anti-tumor and / or anti-cancer immunotherapy. In some embodiments, the methods comprise administering to a subject in need thereof a composition comprising a conjugate comprising a gastrin immunogen conjugated, optionally via a linker, to an immunogenic carrier, in an amount and by a route sufficient to promote entry of anti-tumor T cells into the tumor and / or cancer, thereby promoting anti-tumor and / or anti-cancer immunotherapy. Also provided are pharmaceutical compositions comprising the conjugates for use in treating tumors and cancers, methods for treating tumors and / or cancers, and methods for sensitizing solid tumors and / or cancers in a subject to chimeric antigen receptor-T (CAR-T) cell therapy.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] [Cross-reference with related applications] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 110905, filed on November 6, 2020, the disclosure thereof, which is incorporated herein by reference in its entirety.

[0002] [Technical field] The subject matter of this disclosure relates to compositions and methods for promoting the entry of immunotherapy molecules into tumors, particularly solid tumors. In some embodiments, the subject matter of this disclosure relates to administering humoral and / or cellular immune response inducers to gastrin peptides to a target requiring such inducement, wherein the humoral and / or cellular immune response inducers to gastrin peptides facilitate the arrival of immunotherapy molecules, including, but not limited to, chimeric antigen receptors (CARs) and / or T cells modified to express CARs (referred to here as "CAR-T cells"), into tumors.

[0003] [Reference to the sequence list] The sequence listing relating to this disclosure was created on November 5, 2021, and electronically filed with the United States Patent and Trademark Office as a 5-kilobyte ASCII text file named "1734_10_25_PCT_ST25.txt". The sequence listing, submitted via EFS-Web, is incorporated herein by reference in its entirety with due attribution. [Background technology]

[0004] Gastric adenocarcinoma (stomach cancer) is a common malignant tumor and the second leading cause of cancer death worldwide. With over 50% of patients with localized gastric cancer succumbing to the disease and the approximately 10% improvement in cure rates achieved by adjuvant therapy over surgery unacceptable, new therapeutic targets are urgently needed. The prognosis for patients with advanced gastric cancer is poor, with a 5-year survival rate of only 20-30%. The current standard of treatment for advanced gastric cancer in first-line situations remains the combination of fluoropyrimidine (e.g., 5-fluorouracil; 5FU) and platinum (e.g., cisplatin)-containing chemotherapy agents. Targeted therapy may offer new possibilities for treating gastric cancer. Since the HER2 receptor is found in approximately 20% of gastric cancers, and the ToGA trial demonstrated that trastuzumab (Herceptin) is beneficial in patients with HER2-positive gastric cancer, adding a HER2 receptor antibody to standard chemotherapy may be beneficial. The Cancer Genome Atlas (TCGA) Research Network categorized gastric cancer into four groups based on molecular classifications including EBV (Epstein-Barr virus), MSI (microsatellite instability), GS (genomic stability), and CIN (chromosomal instability). The immune response to the tumor may play a significant role within the EBV and MSI subgroups. Recently, immune checkpoint antibodies have been used, and researchers are exploring whether this immunotherapy is beneficial for gastric cancer. In the KEYNOTE-012 trial, 39 patients who were PD-L1 positive in a phase 1 trial were tested with pembrolizumab, with an overall survival of 11.4 months. The KEYNOTE-059 trial showed that pembrolizumab monotherapy was effective in treating patients with previously treated gastric or gastroesophageal cancer. Another PD-1 antibody, nivolumab, was approved as a first-line treatment for gastric cancer in combination with chemotherapy following the results of the CheckMate-649 clinical trial. Currently, numerous clinical trials are being conducted using various immune checkpoint antibodies, and these drugs offer additional treatment options for gastric cancer patients. However, unfortunately, the median overall survival remains below 12 months. For these reasons, new strategies are needed to improve the response to immunotherapy in gastric cancer patients.One possible reason for the still low response to immune checkpoint antibodies is tumor-infiltrated CD8 within the tumor. + This may be related to a lymphocyte deficiency. Another possible reason for the low response rate may be fibrosis of the tumor microenvironment, which hinders the penetration of therapeutic agents and immune cells. While therapies targeting cancer cell receptors such as HER25 have been shown to improve survival, most chemotherapy drugs used for gastric cancer are not target-specific.

[0005] The gastrointestinal (GI) peptide gastrin is involved in gastric acid secretion and gastrointestinal tract proliferation, and it mediates its effects via the cholecystokinin B receptor, or CCK-BR. Unlike the physiological expression of gastrin in G cells of the gastric antrum, the gastrin gene is also newly overexpressed in non-endocrine epithelial cells of gastric cancer, where it can autocrinely stimulate proliferation. Similarly, CCK-BR is also overexpressed in cancer cells, and this receptor responds to both parasecretory and autocrine stimulation by gastrin. Researchers have studied the expression of gastrin and CCK-BR from resected human gastric cancer and found that most expressed CCK-BR and gastrin. In addition, if blood gastrin levels are elevated due to chronic use of high-dose proton pump inhibitors (PPIs), achlorhydria, or Helicobacter pylori infection, gastrin may also stimulate gastric cancer proliferation. Because gastrin has been shown to stimulate the growth of human gastric cancer, researchers have been studying methods to block the effects of gastrin in gastric cancer using CCK-BR antagonists and their use in human trials.

[0006] Polyclonal antibody stimulants (PAS) are therapeutic immunoproto-cancer vaccines composed of a nine-amino acid epitope derived from the amino-terminal sequence of gastrin-17 conjugated to diphtheria toxoid. PAS exerts immunomodulatory effects by activating both B-28-30 and T cells. PAS stimulates the production of antibodies against different epitopes of G17 and its precursor G17-Gly gastrin peptide. These antibodies can bind to the gastrin peptide and prevent its interaction with CCK-BR on the surface of tumor cells. Preclinical studies have been conducted in several animal models with CCK-BR, including gastric cancer. In animal models, anti-gastrin antibodies produced by PAS have been shown to reduce proliferation and metastasis. Passive immunization with PAS antibodies produced in rabbits improved the survival of gastric cancer-bearing SCID mice compared to controls treated with a diluent.

[0007] To date, 22 clinical trials have been conducted using PAS. Of these, 840 patients were enrolled in 5 clinical trials for the treatment of pancreatic cancer; 234 patients were enrolled in 5 clinical trials for gastric cancer; and 475 patients were enrolled in 10 clinical trials for advanced colon cancer. In the gastric cancer clinical trial (called the GC4 trial), the median survival time for patients with advanced gastric cancer treated with PAS + cisplatin and 5FU was significantly extended (10.8 months) in the group with elevated protective antibody titers against gastrin compared to the group treated with PAS + cisplatin and 5FU without an antibody response (4.8 months). In all 22 trials, the only notable PAS-related adverse events were injection site reactions and fever. [Overview of the project]

[0008] This summary lists several embodiments of the subject matter of the present disclosure, and in many cases lists variations and substitutions of these embodiments. This summary is merely illustrative of the many diverse embodiments. References to one or more representative features of a given embodiment are similarly illustrative. Such embodiments may typically exist with or without the referenced features; similarly, the features may be applicable to other embodiments of the subject matter of the present disclosure, whether or not they are listed in this summary. To avoid excessive repetition, this summary does not list or suggest all possible combinations of such features.

[0009] In some embodiments, the subject matter of the present disclosure relates to methods for promoting antitumor and / or anticancer immunotherapy. In some embodiments, the method comprises, comprises, or comprises, a composition comprising, comprising, or comprising, a conjugate comprising, or comprising, a gastrin immunogen conjugated to an immunogenic carrier, via a linker, in an amount and route sufficient to promote the entry of antitumor immunotherapy molecules, or optionally, CAR or CAR-T cells, into the tumor and / or cancer, thereby promoting antitumor and / or anticancer immunotherapy. In some embodiments, the tumor and / or cancer is gastrointestinal tumor and / or cancer, optionally gastrin-dependent gastrointestinal tumor and / or cancer, and optionally pancreatic tumor and / or cancer. In some embodiments, the tumor and / or cancer is solid tumor and / or cancer of the gastrointestinal tract, optionally solid tumor and / or cancer of the pancreas. In some embodiments, the tumor and / or cancer is gastrin-responsive cancer, such as but not limited to gastrinoma, lung cancer, and / or thyroid cancer. In some embodiments, the immunogenic carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin. In some embodiments, the linker comprises ε-maleimidocaproic acid N-hydroxysuccinate. In some embodiments, the linker and the gastrin peptide are separated by an amino acid spacer, optionally having an amino acid spacer of 1 to 10 amino acids in length, and further optionally having an amino acid spacer of 7 amino acids in length. In some embodiments, the composition further optionally comprises an adjuvant and an oily adjuvant. In some embodiments, the gastrin peptide comprises, essentially comprises, or consists of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4).

[0010] In some embodiments, the subject matter of this disclosure also relates to pharmaceutical compositions for use in the manufacture of pharmaceuticals for treating gastrin-related tumors and / or cancers. In some embodiments, the pharmaceutical composition comprises, is essentially, or consists of one or more conjugates containing a gastrin immunogen in an amount sufficient to promote the entry of antitumor and / or anticancer T cells into gastrin-related tumors and / or cancers.

[0011] In some embodiments, the subject matter of the present disclosure also relates to a pharmaceutical composition for use in the treatment of tumors and / or cancers, optionally gastrin-related tumors and / or cancers, the pharmaceutical composition comprising, essentially, or consisting of a conjugate comprising a gastrin immunogen in an amount sufficient to promote the entry of antitumor and / or anticancer T cells into the tumor and / or cancer.

[0012] In some embodiments, the subject matter of this disclosure also relates to methods for treating tumors and / or cancers in a subject, optionally gastrin-related tumors and / or cancers. In some embodiments, the method comprises the steps of: administering to a subject in an amount and route sufficient to promote the entry of antitumor and / or anti-cancer T cells into a tumor and / or cancer, optionally via a linker, a first composition comprising, essentially, or consisting of a conjugate comprising, conjugated to, an immunogenic carrier, a first composition comprising, conjugated to, or consisting of In some embodiments, the immunogenic carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin. In some embodiments, the linker comprises ε-maleimidocaproic acid N-hydroxysuccinate. In some embodiments, the linker and the gastrin peptide are separated by an amino acid spacer, optionally having an amino acid spacer of 1 to 10 amino acids in length, and further optionally having an amino acid spacer of 7 amino acids in length. In some embodiments, the composition further comprises an adjuvant, optionally an oily adjuvant. In some embodiments, the gastrin peptide comprises, essentially comprises, or consists of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4). In some embodiments, the CAR binds to an antigen selected from the group consisting of claudin 18.2 antigen, glypican 3 antigen, mesothelin antigen, carcinoembryonic antigen, prostate stem cell antigen, and CD70 antigen.

[0013] In some embodiments, the subject matter of this disclosure also relates to a method for sensitizing solid tumors and / or cancers in a subject to chimeric antigen receptor-T (CAR-T) cell therapy. In some embodiments, the method comprises the steps of: administering to a subject in an amount and route sufficient to promote the entry of CAR-T cells into solid tumors and / or cancers, a first composition comprising, essentially, or a conjugate comprising, or conjugate comprising, a gastrin immunogen conjugated to an immunogenic carrier, via an optional linker; and administering to the subject a second composition comprising, essentially, or conjugate comprising CAR-T cells that target antigens present in solid tumors and / or cancers, thereby sensitizing the solid tumors and / or cancers in the subject to CAR-T cell therapy. In some embodiments, the first and second compositions are administered simultaneously. In some embodiments, the first and second compositions are administered at different times. In some embodiments, the first and second compositions are each administered multiple times. In some embodiments, solid tumors and / or cancers are solid gastrointestinal tumors and / or cancers, optionally solid gastrin-dependent gastrointestinal tumors and / or cancers, and optionally solid pancreatic tumors and / or cancers. In some embodiments, solid tumors and / or cancers are solid gastrin-responsive cancers, such as but not limited to gastrinomas, lung cancers, and / or thyroid cancers.

[0014] In some embodiments of the methods of the subject disclosure, the immunogenic carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin. In some embodiments, the linker comprises ε-maleimidocaproic acid N-hydroxysuccinamide ester. In some embodiments, the linker and the gastrin peptide are separated by an amino acid spacer, optionally the amino acid spacer is 1 to 10 amino acids in length, and further optionally the amino acid spacer is 7 amino acids in length. In some embodiments, the first composition further comprises an adjuvant, optionally an oily adjuvant. In some embodiments, the gastrin peptide comprises, consists essentially of, or consists of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4).

[0015] In some embodiments, the methods of the disclosure further comprise subjecting the subject to one or more additional anti-tumor and / or anti-cancer therapies. In some embodiments, the one or more additional anti-tumor and / or anti-cancer therapies comprise, consist essentially of, or consist of administering an immune checkpoint inhibitor to the subject. In some embodiments, the immune checkpoint inhibitor inhibits the biological activity of a target polypeptide selected from the group consisting of cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 receptor (PD-1), and programmed cell death 1 receptor ligand (PD-L1). In some embodiments, the immune checkpoint inhibitor is selected from the group consisting of ipilimumab, tremelimumab, nivolumab, pidilizumab, pembrolizumab, AMP514, AUNP12, BMS-936559 / MDX-1105, atezolizumab, MPDL3280A, RG7446, RO5541267, MEDI4736, and avelumab.

[0016] In some embodiments, the methods of the present disclosure reduce and / or inhibit the growth of tumors and / or cancers in a subject. In some embodiments, the first composition is administered at a dosage selected from the group consisting of from about 50 μg to 1000 μg, from about 50 μg to about 500 μg, from about 100 μg to about 1000 μg, from about 200 μg to about 1000 μg, and from about 250 μg to about 500 μg, and optionally, the administration is repeated one, two, or three times, and optionally, the second dosage is administered one week after the first dosage, and the third dosage, if administered, is administered one or two weeks after the second dosage. In some embodiments, one or more additional anti-tumor and / or anti-cancer therapies are administered following administration of at least the first dosage of the composition. In some embodiments, the CAR binds to an antigen selected from the group consisting of claudin 18.2 antigen, glypican 3 antigen, mesothelin antigen, carcinoembryonic antigen (CEA), prostate stem cell antigen (PSCA), and CD70 antigen. In some embodiments, the tumor and / or cancer is a gastric tumor and / or cancer, a pancreatic tumor and / or cancer, a liver cancer, metastatic lesions derived therefrom, or a metastasis to the subject's stomach, pancreas, liver, lung, brain, or other tissue or organ.

[0017] It is therefore an object of the present disclosure to provide compositions and methods for promoting anti-tumor and / or anti-cancer immunotherapies.

[0018] The objects of the present disclosure are as described above and are achieved in whole or in part by the compositions and methods disclosed herein, and other objects will become apparent as the description proceeds in connection with the accompanying drawings, which are best described below. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] [Figure 1A-C]Figures 1A-1F. Characterization of mouse gastric cancer cells in vitro. (Figure 1A) CCK-BR mRNA expression is increased more than 60-fold in YTN and NCC gastric cancer cells compared to normal mouse tissue. (Figure 1B) PD-L1 mRNA expression by qRT-PCR is significantly increased in gastric cancer YTN and NCC cells compared to normal tissue. (Figure 1C) Exogenous gastrin stimulates the proliferation of mouse NCC gastric cancer cells in vitro (p=0.004). [Figure 1D-E] (Figure 1D) Gastrin peptide expression is detected in NCC gastric cancer cells. (Figure 1E) Gastrin peptide expression is detected in YTN gastric cancer cells. [Figure 1F] Control cells stained with secondary antibody alone show no evidence of nonspecific immunoreactivity. Scale bar is 200 μm. [Figure 2A] Figures 2A-2G. PAS vaccination, alone or in combination with PD-1 Ab, inhibits the growth and metastasis of YTN gastric cancer tumors in mice. (Figure 2A) The time course of YTN tumor volume and the slope of the respective lines for each treatment group are shown. PD-1 Ab monotherapy did not alter the rate of YTN tumor growth compared to PBS-treated controls. Tumor growth in mice treated with PAS monotherapy (p=0.023) or in combination with PD-1 Ab (p=0.0003) was significantly reduced. [Figure 2B-C] (Figure 2B) In mice treated with PAS in combination with PD-1 Ab, the final tumor mass size ex vivo showed a reduction (p=0.09). (Figure 2C) The number of metastases for each treatment group indicates that metastases were observed only in control (PBS-treated) mice and mice treated with PD-1 Ab. No metastases were found in mice treated with PAS monotherapy or in combination with PD-1 Ab. [Figure 2D-G] Metastasis was histologically confirmed by H&E staining. (Figure 2D) Invasive YTN tumor infiltrating the gastric wall. (Figure 2E) Peritoneal dissemination with metastasis. (Figure 2F) Infiltration of YTN tumor cells into mesenteric fat. (Figure 2G) YTN cancer infiltrating the abdominal wall skeletal muscle. [Figure 3A]Figures 3A-3D. Effects of PAS and PD-1 Ab treatment on tumor growth and fibrosis. (Figure 3A) Mean number of Ki67-stained cells ± SEM for each cohort of YTN tumors. Ki67 immunoreactivity in PD-1 Ab tumors was increased compared to PBS-treated controls (p<0.05). Ki67 staining was significantly reduced in tumors of mice treated with PAS monotherapy or in combination with PD-1 Ab (p<0.0001). [Figure 3B] Representative images of tumors that reacted with Ki67 antibodies for each treatment group are shown at low magnification (2X, bar scale, 2mm) and high magnification (40X, box insertion). [Figure 3C-D] (Figure 3C) Representative images of tumors from each treatment group stained with Masson's trichrome for fibrosis (scale bar = 200 μm). (Figure 3D) Mean ± SEM of fibrosis staining, analyzed by integrated density and shown for each treatment. Intratumor fibrosis was reduced in all treatment groups compared to PBS-treated control tumors. Tumors in the combination therapy group also showed less fibrosis than tumors in mice treated with PD-1 Ab monotherapy. (compared to PBS**p<0.01;***p<0.001; compared to PD-1 Ab#p<0.05). [Figure 4A-B] Figures 4A-4D. PAS monotherapy and combination therapy with PD-1 Ab alter the tumor immune cell signature. (Figure 4A) Representative low-magnification tumors (scale bar 600 μm) and high-magnification (20X; insert box) tumors stained with antibodies against CD8+ T lymphocytes from each treatment or control group. (Figure 4B) Columns represent the mean ± SEM number of CD8+ immunoreactive cells in YTN tumor sections from each group. PAS monotherapy and combination therapy with PD-1 Ab significantly increased the number of CD8- immunoreactive T cells in YTN tumors compared to tumors from PBS-treated mice. The combination of PAS and PD-1 Ab also significantly increased the number of CD8+ cells compared to PAS monotherapy. [Figure 4C-D](Figure 4C) Representative low-magnification tumors (scale bar 600 μm) from each treatment group or control group, and high-magnification (20X, box inserted) tumors stained with antibody against arginase to detect M2-polarized tumor-associated macrophages (TAMs). (Figure 4D) Computational analysis of integrated image density confirmed a significant decrease in immunoreactivity in tumors from PAS-treated mice. Immunoreactivity of arginase-positive TAMs was further reduced in tumors from mice treated with both PAS and PD-1 Ab. ***p<0.001 compared to PBS; ###p<0.001 compared to PAS. [Figure 5A-D] Figures 5A-5H. Immunohistochemical analysis of CCK-BR protein expression in human gastric cancer and normal tissue from a human gastric tissue array (US Biomax #BC01011). Gastric cancer (multi-tissue joined panel) tissue array (catalog number BC01011; US ​​Biomax, Inc., Rockville, Maryland, United States of America) was stained overnight at 4°C with CCK-BR antibody (catalog number 77077; Abcam, Waltham, Massachusetts, United States of America) at a titer of 1:200. (Figures 5A-5C) Representative images of gastric cancer with intestinal tissue are shown. (Figure 5D) Representative images of gastric cancer with a diffuse histological type are shown. [Figure 5E-H] (Figure 5E) A typical image of gastric cancer with a diffuse histological type is shown. (Figure 5F) Mucinous adenocarcinoma of gastric cancer. (Figure 5G) Signet ring tissue of gastric cancer; arrows point to signet ring cells. (Figure 5H) Normal human gastric tissue. [Modes for carrying out the invention]

[0020] Headings are included here for reference and to make it easier to find specific sections. These headings are not intended to limit the scope of the concepts described therein, and these concepts are applicable to other sections throughout the specification.

[0021] I. Definition The terminology used herein is for the sole purpose of describing specific embodiments and is not intended to limit the subject matter of this disclosure.

[0022] The following terms are expected to be well understood by those skilled in the art, but their definitions are provided below to facilitate the explanation of the subject matter of this disclosure.

[0023] Unless otherwise defined below, all technical and scientific terms used herein are intended to have the same meaning as those commonly understood by those skilled in the art. References to techniques used herein are intended to refer to techniques commonly understood in the art, including variations or equivalent substitutions of those techniques which would be obvious to those skilled in the art. The following terms are considered to be well understood by those skilled in the art, but their definitions are provided for the convenience of explaining the subject matter of this disclosure.

[0024] It will be understood that many techniques and steps are disclosed in describing the subject matter of this disclosure. Each of these has its own merits, and each can be used in combination with one or more, or possibly all, of the other disclosed techniques.

[0025] Therefore, for clarity, this explanation will refrain from unnecessarily repeating every possible combination of the individual steps. Nevertheless, the specification and claims should be read with the understanding that such combinations are entirely within the scope of the subject matter claimed in this disclosure.

[0026] In accordance with long-standing patent law practice, the terms “a,” “an,” and “the” include the claims and, when used in this application, refer to “one or more.” For example, the phrase “inhibitor” refers to one or more inhibitors, including multiple identical inhibitors. Similarly, the phrase “at least one,” when used herein to refer to an entity, includes, but is not limited to, integer values ​​between 1 and 100 and greater than 100, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, or more such entities.

[0027] Unless otherwise specified, all figures representing quantities of components, reaction conditions, etc., used in this specification and claims should be understood in all cases as being modified by the term “approximately.” The term “approximately,” as used herein with respect to measurable values ​​such as mass, weight, time, volume, concentration, or percentage quantities, means to include variations of ±20%, ±10%, ±0.5%, ±1%, ±0.5%, and ±0.1% from a specified quantity, as such variations are appropriate for carrying out the disclosed method and / or using the disclosed composition. Therefore, unless otherwise specified, the numerical parameters described in this specification and the accompanying claims are approximations that may vary depending on the desired properties to be obtained by the subject matter of this disclosure.

[0028] When used here, the term "and / or" refers to entities that exist individually or in combination, when used in the context of a list of entities. Therefore, for example, the phrase "A, B, C, and / or D" includes A, B, C, and D individually, but also any and all combinations and subcombinations of A, B, C, and D.

[0029] As used herein, the term “antibody” refers to a protein comprising one or more polypeptides substantially encoded by an immunoglobulin gene or a fragment of an immunoglobulin gene. Immunoglobulin genes typically include kappa (κ), lambda (λ), alpha (α), gamma (γ), delta (δ), epsilon (ε), and mu (μ) constant region genes, as well as various immunoglobulin variable genes. The light chain is classified as either κ or λ. In mammals, the heavy chain is classified as γ, μ, α, δ, or ε, which define the classes of immunoglobulins: IgG, IgM, IgA, IgD, and IgE, respectively. Other species have other light and heavy chain genes (for example, certain birds produce what is called IgY, the immunoglobulin type that chickens deposit in egg yolks), and these are also included in the subject of this disclosure. In some embodiments, the term “antibody” refers to an antibody that specifically binds to epitopes present on gastrin gene products, including, but not limited to, epitopes present in the amino acid sequences shown in EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4).

[0030] Typical immunoglobulin (antibody) structural units are known to contain tetramers. Each tetramer consists of two identical polypeptide chains, each pair having one "light" chain (average molecular weight of approximately 25 kilodaltons (kDa)) and one "heavy" chain (average molecular weight of approximately 50-70 kDa). The two identical polypeptide chains are held together in a dimer form by a disulfide bond present within the heavy chain region. The N-terminus of each chain defines a variable region of approximately 100 to 110 or more amino acids, mainly involved in antigen recognition. L ) and variable heavy chain (V H The terms ) refer to these light and heavy chains, respectively.

[0031] Antibodies typically exist as intact immunoglobulins or as many distinctly characterized fragments, which can be produced by digestion with various peptidases. For example, digestion of an antibody molecule with papain cleaves the antibody at the N-terminus of the disulfide bond. This produces three fragments: two identical "Fab" fragments with the N-terminuses of the light and heavy chains, and an "Fc" fragment containing the C-terminus of the heavy chain held together by the disulfide bond. Pepsin, on the other hand, digests the antibody at the C-terminus of the disulfide bond in the hinge region, producing a fragment known as the "F(ab)'2" fragment, which is a dimer of the disulfide-linked Fab fragment. The F(ab)'2 fragment can be reduced under mild conditions, cleaving the disulfide bond in the hinge region and thereby converting the F(ab')2 dimer into two Fab' monomers. The Fab' monomer is essentially a Fab fragment that has part of the hinge region (see Paul, 1993, for a more detailed description of other antibody fragments, e.g.). With respect to these various fragments, the Fab, F(ab')2, and Fab' fragments contain at least one intact antigen-binding domain and are therefore capable of binding to an antigen.

[0032] While various antibody fragments are defined in terms of the digestion of intact antibodies, those skilled in the art will understand that a variety of these fragments (including, but not limited to, Fab' fragments) can be newly synthesized chemically or by utilizing recombinant DNA methods. Therefore, the term “antibody” as used herein also includes antibody fragments produced by modification of whole antibodies or newly synthesized using recombinant DNA methods. In some embodiments, the term “antibody” includes fragments having at least one antigen-binding domain.

[0033] Antibodies can be polyclonal or monoclonal. As used here, the term “polyclonal” refers to antibodies derived from different antibody-producing cells (e.g., B cells) that coexist within a given set of antibodies. Exemplary polyclonal antibodies include, but are not limited to, antibodies that bind to a specific antigen and are found in the blood of an animal after it has produced an immune response to that antigen. However, it is understood that polyclonal preparations of antibodies can also be artificially prepared by mixing at least two non-identical antibodies. Thus, polyclonal antibodies typically contain different antibodies that bind to (i.e., to) different epitopes (sometimes called “antigenic determinants” or simply “determinants”) of any given antigen.

[0034] As used herein, the term “monoclonal” refers to a single antibody species and / or a substantially homogeneous population of a single antibody species. In other words, “monoclonal” refers to an individual antibody or a population of individual antibodies that are identical in specificity and affinity, apart from possible naturally occurring mutations or post-translational modifications that may be present in small amounts. Typically, monoclonal antibodies (mAbs) are produced by a single B cell or its progeny cells (however, the subject matter of this disclosure also includes “monoclonal” antibodies produced by the molecular biological techniques described herein). Monoclonal antibodies (mAbs) are highly specific and are typically produced against a single antigen site. Furthermore, in contrast to polyclonal antibody preparations, a given mAb is typically produced against a single epitope on an antigen.

[0035] In addition to their specificity, mAbs can be advantageous for several purposes because they can be synthesized without contamination by other antibodies. However, the modifier “monoclonal” should not be interpreted as requiring the production of antibodies by some specific method. For example, in some embodiments, the mAbs of the subject matter of this disclosure are prepared using the hybridoma method first described by Kohler et al., 1975, and in some embodiments, they are produced using recombinant DNA methods in bacterial, eukaryotic, or plant cells (see, for example, U.S. Patent No. 4816567, the entirety of which is incorporated herein by attribution). mAbs can also be isolated from phage antibody libraries using techniques described, for example, Clackson et al., 1991 and Marks et al., 1991.

[0036] The antibodies, fragments, and derivatives of the subject matter of this disclosure may also include chimeric antibodies. As used herein in relation to antibodies, the term “chimeric” and its grammatical variations refer to an antibody derivative having a constant region substantially or exclusively derived from the constant region of an antibody of one species and a variable region substantially or exclusively derived from the sequence of a variable region of another species. Certain types of chimeric antibodies are “humanized” antibodies, which are produced, for example, by substituting the complementarity-determining region (CDR) of a mouse antibody with the CDR of a human antibody (see, for example, PCT International Patent Application Publication 1992 / 22653). Thus, in some embodiments, a humanized antibody has a constant region and a variable region other than the CDR substantially or exclusively derived from the corresponding human antibody region, and a CDR substantially or exclusively derived from a non-human mammal.

[0037] The antibodies, fragments, and derivatives of the subject matter of this disclosure may also be single-chain antibodies and single-chain antibody fragments. Single-chain antibody fragments contain amino acid sequences that have at least one of the variable regions and / or CDRs of the whole antibodies described herein, but lack some or all of the constant domains of those antibodies. These constant domains are not necessary for antigen binding but constitute a major part of the structure of the whole antibody.

[0038] Single-chain antibody fragments can overcome some of the problems associated with the use of antibodies that contain some or all of the constant domain. For example, single-chain antibody fragments tend not to have undesirable interactions between the biomolecule and the heavy chain constant domain, or other undesirable biological activity. In addition, because single-chain antibody fragments are considerably smaller than whole antibodies, they have higher capillary permeability and can be localized to bind more efficiently to the target antigen-binding site. Furthermore, antibody fragments can be produced relatively on a large scale in prokaryotic cells, making their production easier. Moreover, because single-chain antibody fragments are relatively small in size, they are less likely to induce an immune response in the recipient than whole antibodies. Single-chain antibody fragments of the subject matter of this disclosure include, but are not limited to, single-chain fragment variable (scFv) antibodies and their derivatives, e.g., tandem di-scFv, tandem tri-scFv, diabody, and triabody, tetrabody, mini-antibody, and minibody.

[0039] The Fv fragment corresponds to the variable fragment at the N-terminus of the immunoglobulin heavy and light chains. The Fv fragment appears to have a lower interaction energy between its two chains than the Fab fragment. H Domain and V L To stabilize the domain binding, they are linked by peptides (see Bird et al., 1988; Huston et al., 1988), disulfide crosslinks (see Glockshuber et al., 1990), and "knob-in-hole" mutations (Zhu et al., 1997). ScFv fragments can be produced by methods well known to those skilled in the art (see, for example, Whitlow et al., 1991 and Huston et al., 1993).

[0040] scFv can be produced in bacterial cells such as E. coli or in eukaryotic cells. One potential drawback of scFv is the monovalent nature of the product and its short half-life, which can hinder the increase in binding strength due to polyvalent bonds. Attempts to overcome these problems include producing divalent (scFv')2 from scFv containing an additional C-terminal cysteine ​​by chemical bonding (Adams et al., 1993; McCartney et al., 1995) or by spontaneous site-directed dimerization of scFv containing an unpaired C-terminal cysteine ​​residue (see Kipriyanov et al., 1995).

[0041] Alternatively, multimerization of scFv can be forced by shortening the peptide linker from 3 to 12 residues to form multispecific antibodies, including, but not limited to, bispecific antibodies (sometimes called "diabodies" (see Holliger et al., 1993)). Linker reduction can also produce scFv trimers (triplespecific antibodies, sometimes called "tribodies"; see Kortt et al., 1997) and tetramers (quadrispecific antibodies, sometimes called "tetrabodies"; see Le Gall et al., 1999). The construction of bivalent scFv molecules can also be achieved by gene fusion with protein dimerizing motifs that form "mini-antibodies" (see Pack et al., 1992) and "mini-bodies" (see Hu et al., 1996). scFv-scFv tandems ((scFv)2) can be produced by linking two scFv units with a third peptide linker (see Kurcz et al., 1995).

[0042] Certain types of multimer scFv are “bispecific T cell engagers” (BiTe; see, e.g., Halland et al., 2020), in which one specificity is binding to T cells and / or immune effector cells, and the other specificity is binding to an antigen of interest. BiTe are described, for example, in U.S. Patents 9,988,452; 1,011,3003; 1,018,3992; 1,030,1391; and 1,035,8492, each of which is incorporated herein by reference in whole. In some embodiments, BiTe includes specificity for binding to the CD3 molecule.

[0043] Bispecific diabodies can be produced through non-covalent binding of two single-chain fusion products, which consist of V domains from one antibody linked by a short linker to V domains of another antibody (see Kipriyanov et al., 1998). The stability of such bispecific diabodies can be enhanced by introduction of the disulfide bridges or “knob-in-hole” mutations described above, or by formation of single-chain diabodies (scDb) in which two hybrid scFv fragments are linked via a peptide linker (see Kontermann et al., 1999). H domains linked by a short linker to V L domains of another antibody.

[0044] Tetravalent bispecific molecules can be generated, for example, by fusing scFv fragments to the CH3 domain of an IgG molecule or to Fab fragments via a hinge region (see Coloma et al., 1997). Alternatively, tetravalent bispecific molecules have been created by fusion of bispecific single-chain diabodies (see Alt et al., 1999). Smaller tetravalent bispecific molecules can be formed by dimerization of either scFv-scFv tandems using linkers containing a helix-loop-helix motif (DiBi minibodies; see Muller et al., 1998) or single-chain molecules containing four antibody variable domains (V H and V L ) in an orientation that prevents intramolecular pairing (tandem diabodies; see Kipriyanov et al., 1999).

[0045] Bispecific F(ab’)2 fragments can be generated by chemical linkage of Fab’ fragments or by heterodimerization via leucine zippers (see Shalaby et al., 1992; Kostelny et al., 1992). Also available are isolated V H and V L domains (see U.S. Patent Nos. 6,172,197; 6,248,516; and 6,291,158).

[0046] The subject matter of this disclosure also includes functional equivalents of anti-gastrin antibodies. As used herein, the term “functional equivalent” refers to an antibody, meaning a molecule having binding properties comparable to those of a given antibody. In some embodiments, chimeric antibodies, humanized antibodies, and single-chain antibodies, as well as fragments thereof, are considered functional equivalents of their underlying corresponding antibodies.

[0047] Functional equivalents also include polypeptides having substantially the same amino acid sequence as the amino acid sequence of the variable region or hypervariable region of the antibody of the subject matter of this disclosure. Where used herein with respect to amino acid sequences, the term “substantially the same” refers to sequences having, in some embodiments, at least 80%, in some embodiments at least 85%, in some embodiments at least about 90%, in some embodiments at least about 91%, in some embodiments at least 92%, in some embodiments at least 93%, in some embodiments at least 94%, in some embodiments at least 95%, in some embodiments at least 96%, in some embodiments at least 97%, in some embodiments at least 98%, and in some embodiments at least about 99% sequence identity to another amino acid sequence, as determined by the FASTA search method according to Pearson & Lipman, 1988. In some embodiments, the identity percentage calculation is performed over the entire length of the amino acid sequence of the antibody of the subject matter of this disclosure.

[0048] Functional equivalents further include antibody fragments having the same or equivalent binding properties as the entire antibody of the subject matter of this disclosure. Such fragments may include one or both Fab fragments, F(ab')2 fragments, F(ab') fragments, Fv fragments, or other fragments containing at least one antigen-binding domain. In some embodiments, the antibody fragment contains all six CDRs of the entire antibody of the subject matter of this disclosure, but fragments containing fewer than all such regions, for example, three, four, or five CDRs, may also be functional equivalents as defined herein. Furthermore, functional equivalents may be members of any one of the following immunoglobulin classes: IgG, IgM, IgA, IgD, and IgE, and their subclasses, as well as other subclasses that may be suitable for non-mammalian subjects, or combinations thereof (e.g., IgY in chicken and other bird species).

[0049] Functional equivalents further include peptides having the same or equivalent characteristics as the entire protein of the subject matter of this disclosure. Such peptides may contain one or more antigens of the entire protein that can induce an immune response in a treated subject.

[0050] Functional equivalents include aptamers and other non-antibody molecules, provided that such molecules have the same or equivalent binding properties as all antibodies of the subject matter of this disclosure.

[0051] The term “comprising” is synonymous with “including,” “containing,” or “characterized by,” and is comprehensive or open-ended, not excluding additional unspecified elements and / or method steps. “Comprising” is a technical term meaning that specified elements and / or steps exist, but other elements and / or steps may be added and still be included within the scope of the relevant subject matter.

[0052] Where used herein, the phrase "consisting of" excludes any elements, steps, or components not specifically mentioned. Note that when the phrase "consists of" appears in a feature clause of the claims rather than immediately following the preceding clause, it limits the claims to only the elements described in that clause; other elements are not excluded from the claims as a whole.

[0053] Where used herein, the phrase “essentially from” limits the scope of the relevant disclosure or claim to the specified materials and / or steps, in addition to those that do not substantially affect the fundamental and novel characteristics of the subject matter disclosed and / or claimed. For example, a pharmaceutical composition “essentially from” one or more pharmaceutically active agents, meaning that the described pharmaceutically active agent is the only pharmaceutically active agent present in the pharmaceutical composition. However, it should be noted that carriers, additives, and / or other inactive agents may, and are likely to be, present in such a pharmaceutical composition and are therefore encompassed within the nature of the phrase “essentially from.”

[0054] With respect to the terms “comprising,” “consisting of,” and “consisting essentially of,” if any of these three terms is used herein, the subject matter described in the claims of this disclosure may include the use of any of the other two terms. For example, in some embodiments, the subject matter of this disclosure relates to compositions comprising antibodies. A person skilled in the art, after reviewing this disclosure, will understand that the subject matter of this disclosure includes compositions essentially comprising the antibodies of the subject matter of this disclosure, as well as compositions comprising the antibodies of the subject matter of this disclosure.

[0055] As used herein, the term "immune cells" refers, but is not limited to, cells of the mammalian immune system, including antigen-presenting cells, B cells, basophils, cytotoxic T cells, dendritic cells, eosinophils, granulocytes, helper T cells, leukocytes, lymphocytes, macrophages, mast cells, memory cells, monocytes, natural killer cells, neutrophils, phagocytes, plasma cells, γδT cells, NKT cells, and mucosal-associated invariant T (MAIT) cells.

[0056] As used herein, the term "immune response" refers to immunity, including but not limited to innate immunity, humoral immunity, cellular immunity, immunity, inflammatory responses, adaptive immunity, autoimmunity, and / or hyperimmunity.

[0057] Where used herein, the term “gastrin-related cancer” means, in some embodiments, a tumor, cancer, or cells derived therefrom in which the gastrin gene product acts as a trophic hormone that stimulates tumor and / or cancer cell proliferation both when applied exogenously to the tumor and / or cancer cells and in vivo via autocrine and paracrine mechanisms. Exemplary gastrin-related cancers include pancreatic cancer, gastric cancer, gastroesophageal cancer, and colorectal cancer. In some embodiments, “gastrin-related cancer” is a tumor, cancer, or cells derived therefrom that itself produces gastrin, and in some embodiments, gastrin may have hormonal and / or feedback effects on the proliferation of tumors, cancers, and / or cells derived therefrom (e.g., gastrinomas), and / or gastrin-responsive tumors and / or cancers (e.g., tumors and / or cells derived therefrom whose proliferation is stimulated by gastrin signaling via gastrin and / or gastrin receptors (e.g., CCK-B receptors)).

[0058] The term "polynucleotide" as used herein includes, but is not limited to, DNA, RNA, complementary DNA (cDNA), messenger RNA (mRNA), ribosomal RNA (rRNA), small hairpin RNA (shRNA), small nuclear RNA (snRNA), short nucleolar RNA (snoRNA), microRNA (miRNA), genomic DNA, synthetic DNA, synthetic RNA, and / or tRNA.

[0059] As used herein, the terms "single-chain variable fragment," "single-chain antibody variable fragment," and "scFv" antibody refer to antibody forms that contain variable regions of only the heavy and light chains, linked by a linker peptide.

[0060] As used herein, the term “subject” refers to any member of any invertebrate or vertebrate species. Accordingly, in some embodiments, the term “subject” is intended to encompass any member of the Animal Kingdom, including, but not limited to, the phylum Chordata (e.g., members of the classes Osteichthyes (bony fish), Amphibia (amphibians), Reptilia (reptiles), Aves (birds), and Mammalia (mammals)) and all orders and families contained therein.

[0061] Accordingly, the compositions and methods of the subject matter of this disclosure are particularly useful for warm-blooded vertebrates. Accordingly, in some embodiments, the subject matter of this disclosure relates to mammals and birds. More specifically provided are compositions and methods derived from and for use in mammals such as humans and other primates, as well as mammals that are endangered and therefore important (such as the Siberian tiger), mammals that are economically important (animals raised on farms for human consumption) and / or mammals that are socially important to humans (animals kept as pets or in zoos), such as non-human carnivores (such as cats and dogs), swine (pigs, sows, and wild boars), ruminants (such as cattle, bulls, sheep, giraffes, deer, goats, bison, and camels), rodents (such as mice, rats, and rabbits), marsupials, and horses. Also provided is the use of the disclosed methods and compositions on endangered bird species kept in zoos, as well as on fowl, more specifically, on domesticated fowl, such as poultry, which are of economic importance to humans, including birds such as turkeys, chickens, ducks, geese, and guinea fowl. Accordingly, also provided is the use of the disclosed methods and compositions on livestock, including, but not limited to, domesticated swine (pigs and boars), ruminants, horses, and poultry.

[0062] As used herein, the terms “T cell” and “T lymphocyte” are interchangeable and used synonymously. Examples include, but are not limited to, naive T cells, central memory T cells, effector memory T cells, cytotoxic T cells, regulatory T cells, helper T cells, and combinations thereof.

[0063] As used herein, the term “therapeutic agent” refers to any drug used to treat, inhibit, prevent, mitigate, reduce the severity of, reduce the likelihood of developing, slow the progression of, and / or cure a disease or disorder, such as, but not limited to, gastrin-related tumors and / or cancer.

[0064] As used herein, the terms “treatment” and “to treat” refer to both therapeutic measures and preventive or deterrent measures, the purpose of which is to prevent or delay (reduce) the targeted pathological condition, to prevent the pathological condition, to pursue or achieve beneficial outcomes, and / or, even if treatment is ultimately unsuccessful, to reduce the likelihood that the individual will develop the condition, disease, or disability. Those who require treatment include those who already have the condition, as well as those who are susceptible to or predisposed to the condition, disease, or disability, or those who should be prevented from developing the condition.

[0065] As used herein, the term “tumor” refers to all precancerous and cancerous cells and tissues whose growth and / or proliferation of any neoplastic cells, whether malignant or benign, and the initiation, progression, proliferation, and maintenance of their metastasis, are directly or indirectly affected by the autocancerous and / or paracancerous effects of gastrin. The terms “cancer” and “tumor” are used herein interchangeably and may refer, but are not limited to, both primary and metastatic solid tumors and carcinomas of any tissue in the subject, including pancreatic cancer, gastric cancer, gastroesophageal cancer, and colorectal cancer (collectively referred herein as “gastrin-related” tumors and / or cancers). As used herein, the terms “cancer” and “tumor” are also intended to refer to multicellular tumors, as well as individual neoplastic or preneoplastic cells. In some embodiments, cancer or tumor includes, but is not limited to, cancer or tumors of epithelial tissue such as carcinomas. In some embodiments, tumor is adenocarcinoma, which, in some embodiments, is adenocarcinoma of the pancreas, liver, stomach, esophagus, colon, or rectum, and / or metastatic cells derived therefrom. In some embodiments, tumors and / or cancers are associated with fibrosis, meaning that one or more areas of fibrosis typically occur in the areas of the tumor and / or cancer as a direct or indirect consequence of the development of the tumor and / or cancer.

[0066] All genes, gene names, and gene products disclosed herein are intended to correspond to homologs and / or orthologues derived from any species to which the compositions and methods disclosed herein are applicable. Accordingly, the terms include, but are not limited to, genes and gene products derived from humans and mice. Where genes or gene products derived from a particular species are disclosed, this disclosure is intended to be illustrative only and should not be construed as limiting unless the context in which it appears explicitly indicates. Accordingly, for example, with respect to the gastrin gene product presented in GENBANK® biological sequence database acceptance numbers: NM_000805.5 and NP_000796.1 (SEQ ID NOs: 11 and 12, respectively), the disclosed human nucleic acid sequences and amino acid sequences are intended to include, but are not limited to, homologous and orthologue gastrin genes and gene products derived from other animals, including other mammals, fish, amphibians, reptiles, and birds. Also included are, but are not limited to, any and all nucleotide sequences encoding gastrin amino acid sequences, including those disclosed in the corresponding GENBANK® registrations (e.g., NP_000796.1 and NM_000805.5; SEQ ID NOs: 11 and 12, respectively).

[0067] II. Compositions containing polyclonal antibody stimulants (PAS) Gastrin vaccine polyclonal antibody stimulants (PAS) contain a nine-amino acid gastrin epitope derived from the N-terminal sequence of gastrin, which is identical in mouse and human in some embodiments and is conjugated to diphtheria toxoid (DT) via a linker molecule. This conjugate is incorporated into an oily adjuvant to create the PAS. PAS stimulates the production of specific, high-affinity polyclonal anti-gastrin antibodies, whereas DT alone was ineffective (Watson et al., 1996). Preclinical studies were conducted in several animal models with gastrin-responsive gastrointestinal (GI) cancers, including colon cancer (Singh et al., 1986; Smith and Solomon, 1988; Upp et al., 1989; Smith et al., 1996), gastric cancer (Smith et al., 1998; Watson et al., 1989), lung cancer (Rehfeld et al., 1989), and pancreatic cancer (Smith et al., 1990; Smith et al., 1991; Smith et al., 1991; Segal et al., 2014).

[0068] In animals, anti-gastrin antibodies produced by PAS have been shown to reduce the growth and metastasis of gastrointestinal tumors (Watson et al., 1995; Watson et al., 1996; Watson et al., 1999a). Both active immunity by PAS and passive immunity by anti-gastrin antibodies produced by PAS (Watson et al., 1999a) have been shown to inhibit tumor growth in animal models of GI cancer (Watson et al., 1998; Watson et al., 1999a).

[0069] PAS has also shown significant prospects in improving survival rates in phase II clinical trials for gastric cancer, as well as in phase II and phase III clinical trials for pancreatic cancer. PAS vaccination has been shown to induce a humoral immune response, as demonstrated by the production of neutralizing antibodies against gastrin. By eliminating gastrin, the vaccine may slow tumor growth and provide long-lasting tumor-killing activity. PAS administration elicits humoral and cellular immune responses against the carcinoembryonic protein gastrin, which is inappropriately expressed (i.e., overexpressed) in a variety of tumors and / or cancers, including, but not limited to, gastric adenocarcinoma and various adenocarcinomas such as PDAC. This inappropriate gastrin expression leads to autocrine and parasecrine proliferative effects. PAS administration, accompanied by the subsequent production of humoral antibodies against gastrin, helps to eliminate this pathological proliferative effect. In addition, PAS-mediated humoral immune responses to gastrin also help reverse the promotion of angiogenesis, avoidance of apoptosis, increased cell migration, and increased invasive enzyme expression associated with inappropriate gastrin expression (Watson et al., 2006).

[0070] In some embodiments, PAS comprises three subunits. The first subunit is a gastrin epitope, which in some embodiments is a peptide containing amino-terminal amino acid residues 1-9 of human G17 having a carboxy-terminal 7-amino acid spacer sequence ending in a cysteine ​​residue. An exemplary sequence of this first subunit is EGPWLEEEE (SEQ ID NO: 2).

[0071] The second subunit of the PAS is a linker that covalently bonds the first subunit to the third subunit. In some embodiments, the linker is ε-maleimidocaproic acid N-hydroxysuccinate (eMCS), but any linker, including non-peptide linkers such as polyethylene glycol linkers, can be used for this purpose, although this is not limited to them.

[0072] The third subunit of PAS is diphtheria toxoid (DT), which is used as a carrier protein to promote the humoral response to the first subunit (particularly the humoral response to the gastric epitope). However, it should be noted that in some embodiments, but not limited to, carrier proteins other than diphtheria toxoid may be used, such as tetanus toxoid or bovine serum albumin.

[0073] In some embodiments, the three subunits are formulated for intramuscular (im) injection, and the formulation has excellent physical, chemical, and pharmaceutical properties. PAS also induces a B-cell response along with the production of neutralizing antibodies against gastrin. This is related to cancer because gastrin increases cell proliferation, promotes angiogenesis, promotes apoptosis evasion, increases cell migration, increases the expression of invasive enzymes, and is associated with fibrosis in a given tumor microenvironment (e.g., PDAC). According to some aspects of the subject matter of this disclosure, when the action of gastrin is blocked, CD8 + Lymphocytes infiltrate the tumor and become more responsive to immunotherapy (e.g., T cell-mediated response). As disclosed herein, PAS also facilitates the T cell response and CD8 cytokine production in response to gastrin stimulation. + It induces cells.

[0074] PAS can be designed as a therapeutic vaccine or immunotherapy. PAS-inducible humoral antibodies are highly specific and typically characterized by high affinity for G17 and Gly-G17.

[0075] PAS consistently induced therapeutically effective levels of antibodies against gastrin. Twenty-two clinical trials involving a total of 1542 patients have been completed. Importantly, treatment with PAS demonstrated a superior safety and tolerability profile, and further extended life in patients with colorectal, gastric, and pancreatic cancer. When used as monotherapy, exemplary doses and schedules were identified as 250 μg / 0.2 ml at weeks 0, 1, and 3.

[0076] In summary, the conclusions that can be drawn from 22 trials and more than 1500 patients treated for PAS are as follows: (a) Nonclinical data demonstrated antitumor efficacy of anti-G17 antibodies both in vitro and in vivo, showing broad therapeutic indices in various cancer models, including a human pancreatic cancer model. (b) PAS can be administered in very safe and well-tolerated doses, without inducing adverse reactions or negative autoimmune effects, and effectively induces a B-cell antibody response to gastrin; and (c) Numerous clinical trials have demonstrated a correlation between the life-extending effect and the generation of an anti-G17 antibody response and improved survival time in gastrointestinal tumors, including pancreatic cancer.

[0077] However, clinical trials have also demonstrated the existence of long-term survivors, suggesting that PAS administration may have yielded further therapeutic effects. While we do not wish to be bound by any particular theory of action, it is possible that PAS treatment may have also induced a T-cell immune response characterized by the activation of cytotoxic T cells and memory cells in these patients.

[0078] III. CARs and methods for producing them Chimeric antigen receptors (CARs) are artificially constructed hybrid proteins or polypeptides that contain an antigen-binding domain (such as scFv, but not limited to) of an antibody linked to one or more T cell signaling domains. The properties of CARs include their ability to redirect T cell specificity and responsiveness to targets selected in a non-MHC-restrictive manner, thereby utilizing the antigen-binding properties of monoclonal antibodies. Non-MHC-restrictive antigen recognition gives CAR-expressing T cells the ability to recognize antigens independently of antigen processing, bypassing the main mechanism of tumor escape. Furthermore, advantageously, when expressed within T cells, CARs do not dimerize with the α and β chains of the endogenous T cell receptor (TCR). CAR and methods for preparing it are generally described in U.S. Patent Nos. 6,410,319; 8,389,282; and 1,005,9923; and U.S. Patent Publications 2007 / 0036773, 2009 / 0180,989, 2009 / 0257,991, 2011 / 0038836, 2012 / 0058051, 2012 / 0213783, and 2012 / 0252742, each of which is incorporated herein by reference in whole.

[0079] Where used herein, the terms “antigen-specific” and “antigen-specific response-inducing” mean that the CAR is immunologically recognizable by specifically binding to an antigen, in some embodiments a tumor-associated antigen (TAA), cancer-associated antigen (CAA), or its immunogenic epitope, such that the binding of the CAR to the antigen induces an immune response.

[0080] As used herein, the term “antigen-specific target region” (ASTR) refers to a region of a CAR that targets (i.e., binds to) a specific antigen and / or epitope. In some embodiments, the CAR of the subject matter of this disclosure comprises one ASTR (i.e., monospecific), and in some embodiments, comprises two targeting regions that target two different antigens and / or epitopes (i.e., bispecific). In some embodiments, the CAR comprises three or more targeting regions that target at least three or more different antigens (i.e., triplicate or multispecific). The targeting regions on the CAR are extracellular. In some embodiments, the antigen-specific targeting region comprises an antibody or its functional equivalent or a fragment or derivative thereof, and in some embodiments, each of the targeting regions targets a different antigen or epitope. The targeting region may comprise a full-length heavy chain, a Fab fragment, a single-chain Fv(scFv) fragment, a bivalent single-chain antibody, or a diabody, each of which is specific to the target antigen. However, there are numerous alternatives, such as bound cytokines (leading to recognition by cells carrying cytokine receptors), aphibodies, naturally occurring receptor-derived ligand-binding domains, soluble protein / peptide ligands for receptors (e.g., on tumor cells), peptides, and vaccines that stimulate immune responses, each of which can be used in various embodiments of the subject matter of this disclosure. In fact, as will be understood by those skilled in the art, almost any molecule that binds to a given antigen with high affinity can be used as an ASTR.

[0081] Accordingly, as used herein, the terms “chimeric antigen receptor,” “CAR,” or “CARs” refer to a modified receptor that transfers antigen specificity onto a cell (e.g., T cell, e.g., naive T cell, central memory T cell, effector memory T cell, or a combination thereof). CARs are also known as artificial T cell receptors, chimeric T cell receptors, or chimeric immune receptors. The CARs of the subject of this disclosure comprise one or more ASTRs, an extracellular domain, a transmembrane domain, one or more costimulatory domains, and an intracellular signaling domain. In embodiments where two or more ASTRs are present, the two or more ASTRs may target at least two different antigens, be arranged in tandem, and be separated by a linker sequence. In some embodiments, the extracellular spacer domain is optional. In some embodiments, the CAR is a monospecific CAR that targets a tumor-related antigen or epitope, and in some embodiments, the tumor may be a tumor characterized by fibrosis.

[0082] In some embodiments, the CAR includes an ASTR that binds to the gastrin gene product or a receptor for which gastrin is a ligand. Exemplary antibodies that bind to gastrin are described in U.S. Patent No. 7,235,376 and No. 8,808,695 (both incorporated herein by reference), and include, but are not limited to, monoclonal antibodies produced by hybridoma 490-1 (ATCC acceptance number PTA-6189), hybridoma 491-1 (ATCC PTA-6190), and hybridoma 495-1 (ATCC acceptance number PTA-6191). Exemplary antibodies that bind to the gastrin receptor CCK-B are described in U.S. Patent No. 8,388,966 and U.S. Patent Application Publication No. 2003 / 0086941 (both incorporated herein by reference). In some embodiments, a paratope and / or a paratope-containing antibody fragment from any of these antibodies can be incorporated into a CAR, and the CAR can then be incorporated into CAR-T cells for use in the compositions and methods of the subject of this disclosure, in some embodiments. In some embodiments, the CAR incorporates paratopes and / or paratope-containing antibody fragments from commercially available anti-CCK-B antibodies, such as, but not limited to, those sold by ThermoFisher Scientific (e.g., catalog numbers PA5-84814, PA5-103116, PA5-32348), Creative Biolabs (e.g., catalog numbers MOB-2496CT, MOB-3741z-S(P), MOB-3741z-F(E), and MOB-3741z), LSBio (e.g., catalog number LS-C128133-20), Novus Biologicals (e.g., catalog number NLS6535), Sigma-Aldrich (e.g., catalog number SAB1402711), Abcam (e.g., catalog numbers ab27441 and ab83180), and others.

[0083] As used herein, the term “costimulatory domain” (CSD) refers to a portion of the CAR that promotes the proliferation, survival, and / or development of memory cells. The CARs of the subject matter of this disclosure may comprise one or more costimulatory domains. In some embodiments, each costimulatory domain comprises a costimulatory domain of one or more members of the TNFR superfamily, CD28, CD137(4-1BB), CD134(OX40), Dap10, CD27, CD2, CD5, ICAM-1, LFA-1(CD11a / CD18), Lck, TNFR-I, TNFR-II, Fas, CD30, CD40, or any combination thereof. Other costimulatory domains (e.g., from other proteins) will be apparent to those skilled in the art and may be used in connection with alternative embodiments of the subject matter of this disclosure.

[0084] As used herein, the term “extracellular spacer domain” (ESD) refers to the hydrophilic region between the ASTR and the transmembrane domain. In some embodiments, the CARs of the subject of this disclosure include an extracellular spacer domain. In some embodiments, the CARs of the subject of this disclosure do not include an extracellular spacer domain. The extracellular spacer domain may include, but is not limited to, an Fc fragment or derivative thereof of an antibody, a hinge region or fragment or derivative thereof of an antibody, a CH2 region of an antibody, a CH3 region of an antibody, an artificial spacer sequence, or a combination thereof. Examples of extracellular spacer domains include, but is not limited to, the CD8α hinge, and artificial spacers made from polypeptides that may be as small as, for example, the CH1 and CH3 domains of Gly3 or IgG (including, but not limited to, human IgG4). In some embodiments, the extracellular spacer domain is any one or more of the following: (i) the hinge, CH2, and CH3 regions of IgG4; (ii) the hinge region of IgG4; (iii) the hinge and CH2 region of IgG4; (iv) the hinge region of CD8α; (v) the hinge, CH2, and CH3 regions of IgG1; (vi) the hinge region of IgG1; (vi) the hinge and CH2 region of IgG1; and / or (vii) the hinge region of IgD. Other extracellular spacer domains will be apparent to those skilled in the art and may be used in connection with any embodiment of the subject matter of this disclosure.

[0085] In some embodiments, the binding domain of the CARs of the subject of this disclosure is followed by a hinge region, which refers to a region that moves the antigen-binding domain away from the effector cell surface to enable proper cell / cell contact, antigen binding, and activation (see, e.g., Patel et al., 1999). In some embodiments, the hinge region is an immunoglobulin hinge region, which may be a wild-type immunoglobulin hinge region or a modified immunoglobulin hinge region. Other exemplary hinge regions used in the CARs described herein include hinge regions derived from the extracellular regions of type 1 membrane proteins such as CD8a, CD4, CD28, and CD7, which may be wild-type hinge regions derived from these molecules or modified forms. In some embodiments, the hinge region is an IgD hinge region or a subsequence thereof.

[0086] Where used herein, the term “modified hinge region” means (a) a wild-type hinge region having up to 30% amino acid changes (e.g., up to 25% amino acid changes, up to 20% amino acid changes, up to 15% amino acid changes, up to 10% amino acid changes, or up to 5% amino acid changes, including, but not limited to, amino acid substitutions, additions, and / or deletions, in some embodiments; (b) a wild-type hinge region having up to 30% amino acid changes (e.g., up to 25% amino acid changes, up to 20% amino acid changes, up to 15% amino acid changes, including, but not limited to, amino acid substitutions, additions, and / or deletions, in some embodiments) (c) A portion of the wild-type hinge region that is at least 10 amino acid lengths (e.g., at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more amino acid lengths), which in some embodiments involves a change of up to 10% of amino acids, or up to 5% of amino acids; or (c) a portion of the wild-type hinge region that includes a core hinge region (which in some embodiments may be 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid lengths). When a modified hinge region interposes and links the binding domain and another region (e.g., a transmembrane domain) in the CAR described herein, the chimeric fusion protein can maintain specific binding to its target (e.g., a tumor-associated antigen or epitope).

[0087] As used herein, the terms “intracellular signaling domain” (ISD) or “cytoplasmic domain” refer to the portion of the CAR that transmits effector functional signals and instructs the cell to perform its specific function. Examples of effector functional signaling domains include, but are not limited to, the zeta chain of the T cell receptor complex or any of its homologs (e.g., eta chain, FcεR1γ and β chains, MB1(Igα) chain, B29(Igβ) chain, etc.), the human CD3 zeta chain, CD3 polypeptides (delta and epsilon), syk family tyrosine kinases (Syk, ZAP70, etc.), src family tyrosine kinases (Lck, Fyn, Lyn, etc.), and other molecules involved in T cell transduction such as CD2, CD5, and CD28. Other intracellular signaling domains will be apparent to those skilled in the art and may be used in connection with any embodiment of the subject matter of this disclosure.

[0088] As used herein, the terms “linker,” “linker domain,” and “linker region” refer to an oligo or polypeptide region of about 1 to 100 amino acids in length that links together any domains and / or regions of a CAR of the subject matter of this disclosure. In some embodiments, the linker includes, and is essentially composed of, or consists of, mobile residues such as glycine and serine, allowing adjacent protein domains to move freely from one another. Longer linkers can be used when it is desirable to prevent sterically interfering two adjacent domains, as in the case of bispecific, tripspecific, and multispecific CARs. Linkers may be cleavable or non-cleavable. Examples of cleavable linkers include 2A linkers (e.g., T2A; see U.S. Patent No. 8802374, which is incorporated herein by reference in whole), 2A-like linkers, or their functional equivalents, and combinations thereof. In some embodiments, the linker includes picornavirus 2A-like linkers, porcine tesshouvirus (P2A), cis-active hydrolase element (CHYSEL) sequences of tesea signalavirus (T2A), or combinations, variants, and functional equivalents thereof. In some embodiments, the linker sequence may include the Asp-Val / Ile-Glu-X-Asn-Pro-Gly2A-Pro2B motif, which results in cleavage between 2A glycine and 2B proline. Other linkers will be apparent to those skilled in the art and may be used in connection with any embodiment of the subject matter of this disclosure.

[0089] As used herein, the term “transmembrane domain” (TMD or TD) refers to a region of a CAR that crosses the cell membrane. The transmembrane domains of CARs in the subject matter of this disclosure are transmembrane regions of transmembrane proteins (e.g., type I transmembrane proteins), artificial hydrophobic sequences, or combinations thereof. Other transmembrane domains will be apparent to those skilled in the art and may be used in connection with any embodiment of the subject matter of this disclosure.

[0090] CARs and T cells modified to express CARs can be described as "first-generation," "second-generation," "third-generation," or "fourth-generation" based on the various components present in the CAR. "First-generation" CARs include an antigen-binding domain, a transmembrane domain, and an intracellular domain, typically the CD3 zeta intracellular domain. "Second-generation" CARs further include a costimulatory domain. "Third-generation" CARs further include, but are not limited to, other signaling domains such as a 4-IBB signaling domain and / or an OX40 signaling domain. "Fourth-generation" CAR T cells are typically characterized by the presence of a second- or third-generation CAR and are further modified to express a proliferative cytokine (e.g., IL-12; Pegram et al., 2012) or an additional costimulatory ligand (e.g., 4-1BBL; Stephan et al., 2007).

[0091] Accordingly, the subject matter of the present disclosure, in some embodiments but not limited to, provides CARs that bind to tumor-associated antigens and / or epitopes, meaning that the antigens and / or epitopes to which the CARs of the present disclosure bind are expressed by tumor cells but not by non-tumor cells.

[0092] In some embodiments, the subject matter of this disclosure provides nucleic acid molecules encoding chimeric antigen receptors (CARs) directed to tumor-associated epitopes. In some embodiments, the nucleic acid may be DNA and / or RNA, optionally mRNA, encoding the CAR. In some embodiments, the nucleic acid molecule encodes a CAR comprising an antibody or antibody fragment comprising an intracellular signaling domain including a binding domain, a transmembrane domain, and a stimulating domain, wherein the binding domain binds to a tumor-associated antigen (TAA) or epitope.

[0093] CARs also include a transmembrane domain (TD), and in some embodiments, the TD of the CARs of this disclosure is a TD of a protein selected from the group consisting of T cell receptor (TCR) alpha chain, TCR beta chain, TCR zeta chain, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154. In some embodiments, the TD includes the amino acid sequence FWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 5) or the amino acid sequence FWALVVVAGVLFCYGLLVTVALCVIWT (SEQ ID NO: 6), corresponding to the transmembrane domains of human and mouse CD28 molecules, respectively. Since the TD generally only serves to fix the CAR to the membrane of the cell expressing the CAR, modifications of known TD sequences are also permissible as long as the modifications do not disrupt the TD's ability to function as a TD. Accordingly, in some embodiments, TD includes an amino acid sequence having at least one, two, or three but 20, 10, or 5 modifications of the amino acid sequence FWVLVVVGGVLACYSLLVTVAFIIFWV (i.e., amino acids 34-60 of the human T cell-specific surface glycoprotein CD28 precursor of GENBANK® acceptance number NP_001230007.1, SEQ ID NO: 5) or the amino acid sequence WWALVVVAGVLFCYGLLVTVALCVIWT (i.e., amino acids 151-177 of the mouse T cell-specific surface glycoprotein CD28 precursor of GENBANK® acceptance number NP_031668.3; SEQ ID NO: 6), or an amino acid sequence having at least 95% identity therewith.

[0094] Nucleic acid molecules of the subject matter of this disclosure may, in some embodiments, encode an anti-TAA binding domain linked to a TD by an extracellular hinge region, and / or a TD linked to an intracellular domain via an intracellular hinge region. The extracellular hinge region provides mobility between the binding domain and the TD to the CAR, and in some embodiments, can influence cytokine secretion and cell-mediated death of target cells by the CAR (Sadelain et al., 2009). Non-limiting examples of extracellular and intracellular hinge regions that can be used in the CAR include the Fc regions of immunoglobulins and immunoglobulin-like domains from CD8α or CD28 (e.g., extracellular and intracellular hinges of human CD8 and CD28 disclosed in U.S. Patent No. 8,465,743). In some embodiments, the CAR of the present disclosure includes a hinge region, and in some embodiments, but not limited to, a hinge region of an immunoglobulin delta chain including amino acids 101-158 of GENBANK® acceptance number AAA52771.1 (SEQ ID NO: 13), or a subsequence thereof.

[0095] CARs also generally include intracellular domains comprising one or more costimulatory domains and one or more signaling domains. Thus, isolated nucleic acid molecules of the subject of this disclosure further include sequences encoding costimulatory domains. In some embodiments, the costimulatory domains include intracellular domains of costimulatory molecules selected from the group consisting of ligands that specifically bind to CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen 1 (LFA-1), CD7, LIGHT, NKG2C, B7-H3, CD83, and any combination thereof. Certain non-limiting examples of costimulatory domains of the subject of this disclosure include, but are not limited to, amino acid sequences derived from human or mouse CD28 polypeptides, comprising amino acids 123-220 (SEQ ID NO: 14) of GENBANK® acceptance number NP_006130.1 or amino acids 124-218 (SEQ ID NO: 15) of GENBANK® acceptance number NP_031668.3. Modifications to the co-stimulatory domain that do not significantly affect the ability of the domain to function as a co-stimulatory domain are also permitted. Accordingly, in some embodiments, the encoded co-stimulatory domain includes an amino acid sequence having at least one, two, or three but 20, 10, or 5 modifications to either amino acid 123-220 (SEQ ID NO: 14) of GENBANK® acceptance number NP_006130.1 or amino acid 124-218 (SEQ ID NO: 15) of GENBANK® acceptance number NP_031668.3, or an amino acid sequence having at least 95% identity with it.

[0096] The nucleic acid molecules of the subject matter of this disclosure also encode CARs that include at least one intracellular signaling domain. Exemplary and non-limiting intracellular signaling domains include those derived from 4-1BB and / or CD3 zeta. More specifically, the intracellular signaling domain may include a human CD3 zeta intracellular signaling domain containing amino acids 52-163 (SEQ ID NO: 16) of GENBANK® acceptance number NP_000725.1, or a mouse CD3 zeta intracellular signaling domain containing amino acids 52-164 (SEQ ID NO: 17) of GENBANK® acceptance number NP_001106862.1. Hereinafter, modifications to the sequence of the intracellular signaling domain are also permissible, as long as the modification does not disrupt the ability of the intracellular signaling domain to function as an intracellular signaling domain. In some embodiments, the encoded intracellular signaling domain includes at least one, two, or three amino acid sequences having 20, 10, or 5 modifications or less of the amino acid sequence shown in amino acids 52-163 of GENBANK® acceptance number NP_000725.1 (SEQ ID NO: 16) or amino acids 52-164 of GENBANK® acceptance number NP_001106862.1 (SEQ ID NO: 17), or includes an amino acid sequence having at least 95% identity thereto.

[0097] In some embodiments, a co-stimulatory domain is fused to an intracellular signaling domain to create a dual-function intracellular domain. For example, but not limited to, one of the co-stimulatory domains disclosed herein can be fused in-frame with one of the intracellular signaling domains disclosed herein. In some embodiments, the intracellular domain comprises amino acids 123-220 (SEQ ID NO: 14) of GENBANK® acceptance number NP_006130.1 fused to amino acids 52-163 (SEQ ID NO: 16) of GENBANK® acceptance number NP_000725.1, where the sequence containing the intracellular domain is expressed as a single polypeptide chain within the same frame.

[0098] CARs may also include, but are not limited to, leader sequences such as CD8 leader sequences. An unrestricted example of a CD8 leader sequence that may be included in a CAR is the human CD8 leader sequence corresponding to amino acids 1-21 (sequence number: 18) of entry number NP_741969.1 in the GENBANK® biological sequence database.

[0099] In some embodiments, the nucleic acid sequence encoding the chimeric antigen receptor (CAR) of the subject of this disclosure comprises (i) a binding domain that binds to a tumor-exclusive epitope of human MUC1 polypeptide, and (ii) a CD3 zeta signaling domain. In some embodiments, the nucleic acid further encodes a co-stimulatory signaling domain, and in some embodiments, the co-stimulatory signaling domain is selected from the group consisting of a CD28 signaling domain and a 4-1BB signaling domain.

[0100] The subject matter of this disclosure provides, in some embodiments, a chimeric antigen receptor (CAR) molecule comprising a binding domain, a transmembrane domain (TD), and an intracellular domain, wherein the binding domain binds to a TAA or its epitope. In some embodiments, the binding domain is a partial sequence of an antibody that binds to a TAA or its epitope, or a fragment thereof, including the claudin 18.2 antigen, glypican 3 antigen, mesothelin antigen, carcinoembryonic antigen (CEA), prostate stem cell antigen (PSCA), and CD70 antigen, or a paratope of the antibody, and the binding domain is optionally human or humanized. In some embodiments, the binding domain is scFv.

[0101] In some embodiments of the CAR molecules of this disclosure, the TD includes a protein selected from the group consisting of T cell receptor (TCR) alpha chain, TCR beta chain, TCR zeta chain, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154. In some embodiments, TD is (i) amino acids 34-60 of the human T cell-specific surface glycoprotein CD28 precursor of GENBANK® acceptance number NP_001230007.1, or amino acids 151-177 (SEQ ID NO: 15) of the mouse T cell-specific surface glycoprotein CD28 precursor of GENBANK® acceptance number NP_031668.3; (ii) amino acids 34-60 of the human T cell-specific surface glycoprotein CD28 precursor of GENBANK® acceptance number NP_001230007.1, or GENBANK ( (iii) Containing a sequence having at least 95% identity with amino acids 151-177 (SEQ ID NO: 15) of the mouse T cell-specific surface glycoprotein CD28 precursor of registered trademark (acceptance number NP_031668.3); or (iii) containing amino acids 34-60 of the human T cell-specific surface glycoprotein CD28 precursor of GENBANK (registered trademark) (acceptance number NP_001230007.1) or amino acids 151-177 (SEQ ID NO: 15) of the mouse T cell-specific surface glycoprotein CD28 precursor of GENBANK (registered trademark) (acceptance number NP_031668.3).

[0102] In some embodiments of the CAR molecules of this disclosure, the binding domain is linked to the transmembrane domain by a hinge region. In some embodiments, the hinge region comprises amino acids 101-158 (SEQ ID NO: 13) of GENBANK® acceptance number AAA52771.1, or a portion thereof.

[0103] In some embodiments, the CAR molecule of the present disclosure further comprises a co-stimulatory domain, optionally a co-stimulatory domain containing a functional signaling domain of a protein selected from the group consisting of OX40, CD2, CD3, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), and 4-1BB (CD137), or optionally an amino acid sequence having at least 95% identity thereto.

[0104] In some embodiments, the CAR molecule may further include an intracellular signaling domain, in some embodiments, the intracellular signaling domain includes a 4-1BB functional signaling domain, a CD3 zeta functional signaling domain, or both, an amino acid sequence having at least one, two, or three but 20, 10, or 5 or fewer modifications of the aforementioned amino acid sequence, or an amino acid sequence having at least 95% identity thereto.

[0105] In some embodiments, the CAR molecule of the present disclosure further comprises a leader sequence, optionally a leader sequence comprising an amino acid sequence derived from amino acids 1-21 of a human CD8 alpha chain precursor (see, for example, GENBANK® acceptance number NP_001139345.1), or an amino acid sequence having at least 95% identity thereto.

[0106] In some embodiments, the nucleic acid molecule of the Disclosure is present in a vector, optionally in an expression vector. Accordingly, the Subject Matter of the Disclosure provides a vector comprising, in some embodiments, a nucleic acid molecule of the Subject Matter of the Disclosure and / or a nucleotide sequence encoding the CAR of the Subject Matter of the Disclosure. In some embodiments, the vector is selected from the group consisting of DNA vectors, RNA vectors, plasmids, lentiviral vectors, adenovirus vectors, adeno-associated virus (AAV) vectors, and retroviral vectors, any of which may be an expression vector in some embodiments. In some embodiments, the vector of the Subject Matter of the Disclosure further comprises a promoter, optionally involuntarily ligated to the nucleic acid molecule or nucleotide sequence. In some embodiments, the vector is an in vitro transcription vector. In some embodiments, the nucleic acid molecule or nucleotide sequence further comprises and / or encodes a polyadenylation signal and / or poly(A) tail. In some embodiments, the nucleic acid molecule or nucleotide sequence in the vector further comprises a 3'-UTR.

[0107] Accordingly, in some embodiments, the subject of the present disclosure provides a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR) of the subject of the present disclosure, the CAR comprising an antigen-binding domain that binds to TAA or its epitope, a transmembrane domain, a CD28 costimulatory signaling domain, and a CD3 zeta signaling domain. In some embodiments, the antigen-binding domain is an antibody or fragment thereof that binds to TAA or its epitope.

[0108] In some embodiments of the subject matter of this disclosure, the vector is present in a host cell. In some embodiments, the host cell is a human T cell, optionally CD8 + These are T cells.

[0109] The subject matter of this disclosure also provides, in some embodiments, methods for producing cells expressing the anti-TAA CAR disclosed herein. In some embodiments, the method includes transducing a vector encoding the anti-TAA CAR disclosed herein into T cells.

[0110] In some embodiments, the subject matter of this disclosure also provides a method for producing a population of RNA-modified cells, which in some embodiments comprises introducing in vitro transcribed RNA or synthetic RNA into cells, wherein the RNA comprises a nucleic acid encoding the anti-TAA CAR molecule of the subject matter of this disclosure.

[0111] The subject matter of this disclosure also provides, in some embodiments, methods for expressing nucleic acids encoding CARs in vivo.

[0112] In some embodiments, the subject matter of the present disclosure provides a method for producing a persistent population of genetically modified T cells in a human or other mammal diagnosed with cancer. In some embodiments, the method of the present disclosure comprises administering to a human or other mammal T cells genetically modified to express a CAR comprising an antigen-binding domain that binds to a TAA or its epitope, a transmembrane domain, a costimulatory signaling region including a CD28 signaling domain, and a CD3 zeta signaling domain, wherein the persistent population of genetically modified T cells persists in humans for at least one month after administration. In some embodiments, the persistent population of genetically modified T cells includes at least one T cell administered to a human and / or its progeny cells. In some embodiments, the persistent population of genetically modified T cells includes memory T cells. In some embodiments, the persistent population of genetically modified T cells persists in humans for at least 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 2 years, or at least 3 years after administration. In some embodiments, the cancer is a gastric cancer, and in some embodiments, the cancer is a cancer characterized by fibrosis.

[0113] The subject matter of this disclosure also provides, in some embodiments, methods for growing populations of genetically modified T cells in humans or other mammals diagnosed with cancer. In some embodiments, the method comprises administering to humans or other mammals genetically modified to express a CAR comprising an antigen-binding domain that binds to a tTAA or its epitope, a transmembrane domain, a costimulatory signaling region including a CD28 signaling domain, and a CD3 zeta signaling domain, the administered genetically modified T cells produce a population of progeny T cells in humans. In some embodiments, the human progeny T cells include memory T cells. In some embodiments, the T cells administered to humans are autologous T cells. In some embodiments, the population of progeny T cells persists in humans for at least 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 2 years, or at least 3 years after administration.

[0114] The subject matter of this disclosure also provides, in some embodiments, methods for regulating the amount of cytokines secreted by T cells. In some embodiments, the method involves genetically modifying T cells to express the CAR of the subject matter of this disclosure. In some embodiments, the amount of cytokines secreted by T cells reduces the proliferation of regulatory T cells in vivo, in vitro, or ex vivo.

[0115] In some embodiments, the subject matter of this disclosure provides methods for reducing the amount of activation-inducible calcium influx into T cells. In some embodiments, the methods include genetically modifying T cells to express the CAR of the subject matter of this disclosure. In some embodiments, activation-inducible cell death of T cells is prevented in vivo, in vitro, or ex vivo by reducing the amount of activation-inducible calcium influx into T cells.

[0116] IV. Treatment and / or prevention methods using CAR The subject matter of this disclosure also provides methods for treating and / or preventing diseases, conditions, or disorders associated with undesirable gastrin expression and / or biological activity, and / or fibrosis, where fibrosis may, in some embodiments, be fibrosis that inhibits the access of cells, tissues, or organs to the therapeutic compositions of the subject matter of this disclosure.

[0117] In some embodiments, the methods of the present disclosure relate to providing an antitumor and / or anticancer therapy to a mammal, or optionally to a human. In some embodiments, the methods of the present disclosure include administering an effective amount of cells expressing the subject matter of the present disclosure to a mammal or a human. In some embodiments, the cells expressing the CAR molecule may be autologous T cells, and in some embodiments, the cells may be allogeneic T cells.

[0118] The methods of the subject matter of this disclosure also relate to the treatment of mammals with a disease, condition, or disorder, and optionally to humans, and the methods include administering an effective amount of cells containing the CAR molecule of the subject matter of this disclosure to a mammal. In some embodiments, the disease, condition, or disorder is selected from proliferative disorders such as cancer or malignant tumors, or precancerous conditions such as myelodysplasia, myelodysplastic syndromes, or preleukemia, or is a non-cancer-related indication resulting from or associated with abnormal gastrin signaling due to abnormal gastrin expression or fibrosis. In some embodiments, the gastrin-related disease, condition, or disorder is a tumor or cancer expressing gastrin or its receptor, and includes, but are not limited to, colon tumors and / or cancers, gastric tumors and / or cancers, pancreatic tumors and / or cancers, thyroid tumors and / or cancers, lung tumors and / or cancers, hepatocellular tumors and / or cancers, and esophageal tumors and / or cancers.

[0119] In some embodiments, cells expressing CAR molecules are administered as part of a combination therapy that also includes the administration of a drug that improves one or more side effects associated with the administration of cells expressing CAR molecules.

[0120] The subject matter of this disclosure also provides methods for treating solid tumors in human patients, optionally solid tumors associated with the fibrous tumor microenvironment. In some embodiments, the method involves administering to a human patient a pharmaceutical composition comprising an antitumor-effective dose of modified human T cells, optionally a population of modified autologous T cells, wherein the T cells comprise a nucleic acid sequence encoding the CAR of the subject matter of this disclosure. In some embodiments, the CAR comprises an antigen-binding domain that binds to a TAA or its epitope, optionally a hinge domain, a transmembrane domain, a CD28 costimulatory signaling region, and a CD3 zeta signaling domain. In some embodiments, the antitumor-effective dose of T cells is 10 per kg of body weight of a human patient. 4 from 10 9 These are cells. In some embodiments, the antitumor effective dose of T cells is 10 per kg of body weight of a human patient. 5 from 10 6 The cells are cells. In some embodiments, the antigen-binding domain is an antibody or fragment thereof that binds to a TAA or its epitope. In some embodiments, the antigen-binding fragment comprises a Fab fragment or scFv. In some embodiments, the modified T cells replicate in vivo in a human patient and / or form memory T cells in a human patient. In some embodiments, the modified T cells are administered intravenously to a human patient. In some embodiments, the modified T cells persist in a human patient for at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 30, or 36 months after optional administration.

[0121] The subject matter of this disclosure also relates, in some embodiments, to methods for stimulating a T cell-mediated immune response against a target cell population or tissue in mammals, or optionally in humans. In some embodiments, the method comprises administering an effective amount of cells genetically modified to express a CAR to a mammal, the CAR comprising an antigen-binding domain that binds to a TAA or its epitope, a transmembrane domain, a co-stimulatory signaling region including a CD28 signaling domain, and a CD3 zeta signaling domain.

[0122] In some embodiments, a method for inducing antitumor immunity in mammals comprises administering an effective amount of cells genetically modified to express a CAR to the mammal, the CAR comprising an antigen-binding domain that binds to a TAA or its epitope, a transmembrane domain, a costimulatory signaling region including a CD28 signaling domain, and CD3 zeta signaling, thereby inducing antitumor immunity in the mammal.

[0123] The subject matter of this disclosure also relates, in some embodiments, to methods for treating mammals having diseases, disorders, or conditions associated with the expression of TAA or its epitope. In some embodiments, the method involves administering an effective amount of cells genetically modified to express a CAR comprising an antigen-binding domain, a transmembrane domain, a costimulatory signaling region including a CD28 signaling domain, and a CD3 zeta signaling domain that binds to TAA or its epitope, thereby treating the mammal. In some embodiments, the cells are autologous T cells.

[0124] The subject matter of this disclosure also relates, in some embodiments, to methods for treating humans with cancer. In some embodiments, the method involves administering to humans T cells genetically modified to express a CAR comprising an antigen-binding domain that binds to a TAA or its epitope, a transmembrane domain, a costimulatory signaling region including a CD28 signaling domain, and a CD3 zeta signaling domain.

[0125] V. Pharmaceutical Compositions In some embodiments, the subject matter of this disclosure provides pharmaceutical compositions that can be used in the methods of the subject matter of this disclosure.

[0126] As used herein, “pharmaceutical composition” means a composition to be used as part of a treatment or other method administered to a subject in need of it. In some embodiments, the subject in need is a subject having a tumor and / or cancer in which at least one symptom, characteristic, or outcome is expected to be at least partially improved due to the biological activity of the pharmaceutical composition acting directly and / or indirectly on tumor and / or cancer and / or related cells.

[0127] Techniques for preparing pharmaceutical compositions are known in the art, and in some embodiments, the pharmaceutical composition is formulated based on the target to which the pharmaceutical composition will be administered. For example, in some embodiments, the pharmaceutical composition is formulated for use in human subjects. Thus, in some embodiments, the pharmaceutical composition is pharmaceutically acceptable for use in humans.

[0128] In some embodiments, the pharmaceutically acceptable compositions of the subject matter of this disclosure include a first agent that induces and / or provides an active and / or passive humoral immune response to a gastrin peptide and / or CCK-B receptor; and an immune checkpoint inhibitor (CPI). In some embodiments, the first agent is selected from the group consisting of a gastrin peptide, an anti-gastrin antibody, and an anti-CCK-R antibody. In some embodiments, the first agent includes a gastrin peptide, optionally comprising, essentially being, or comprising an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4). In some embodiments, the glutamic acid residue at amino acid position 1 in any of SEQ ID NOs: 1-4 is a pyroglutamic acid residue. In some embodiments, the gastrin peptide is conjugated to an immunogenic carrier, which is optionally selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin. In some embodiments, the gastrin peptide is conjugated to the immunogenic carrier via a linker, which optionally comprises ε-maleimidocaproic acid N-hydroxysuccinate.

[0129] In some embodiments, the linker and the gastrin peptide are separated by an amino acid spacer, which optionally has a length of 1 to 10 amino acids, and further optionally has a length of 7 amino acids.

[0130] The pharmaceutically active ingredients of the subject of this disclosure, designed to induce a humoral immune response, may in some embodiments further comprise an adjuvant, optionally an oily adjuvant. Exemplary adjuvants include, but are not limited to, montanide ISA-51 (Seppic, Inc.); QS-21 (Aquila Pharmaceuticals, Inc.); Alrasel A; oleic acid; tetanus helper peptide; GM-CSF; cyclophosamide; Bacillus carmette-guerlain (BCG); and corynbacterium parvum. Parvum); Levamisole, Azimezone; Isoprinisone; Dinitrochlorobenzene (DNCB); Keyhole Limpet Hemocyanin (KLH) containing Freund's adjuvants (complete and incomplete); Mineral gel; Aluminum hydroxide (alum); Lysolecithin; Pluronic polyol; Polyanion; Peptide; Oil emulsion; Nucleic acid (e.g., dsRNA); Dinitrophenol; Diphtheria toxin (DT); Toll-like receptor (TLR, e.g., TLR3, TLR4, TLR7, TLR8 or TLR9) agonist (e.g., endotoxin, e.g., lipopolysaccharide (LPS)); Monophosphoryl lipid A (MPL); Polyinosine / polycytidic acid (Poly-ICLC / HILTONOL®); Oncovir, Inc., Washington, DC, United States of This includes: America; IMO-2055, glucopyranosyllipid A (GLA), QS-21 - a saponin extracted from the bark of the soapberry tree (also known as soapbark wood or soapbark); resikimod (a TLR7 / 8 agonist); CDX-1401 - a fully human monoclonal antibody specific to the dendritic cell receptor DEC-205 bound to the NY-ESO-1 tumor antigen; Juvaris cationic lipid DNA complex; Vaxfectin; and combinations thereof.

[0131] In some embodiments of the pharmaceutical compositions of the present disclosure, the first agent comprises a gastrin peptide effective in inducing an anti-gastrin humoral response, comprising, essentially, or consisting of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4), and the second agent comprises an immunotherapy molecule effective in inducing or promoting a cellular immune response against gastrin-related tumors or cancer when administered to a subject having a gastrin-related tumor or cancer.

[0132] In some embodiments of the pharmaceutical compositions of the present disclosure, the first agent comprises one or more anti-CCK-B receptor antibodies and is present in the pharmaceutical composition in an amount sufficient to reduce or inhibit gastrin signaling via CCK-B receptors present on the gastrin-related tumor or cancer when administered to a subject having a gastrin-related tumor or cancer.

[0133] The pharmaceutical compositions of the subject matter of this disclosure are used in some embodiments to treat gastrin-related tumors and / or cancers. In some embodiments, the pharmaceutical compositions of the subject matter of this disclosure are intended to treat pancreatic cancer.

[0134] The compositions described herein, in some embodiments, include compositions comprising a pharmaceutically acceptable carrier. Suitable formulations include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostatic agents, bactericidal antibiotics, and solutes which make the formulation isotonic with the body fluids of the recipient to which the formulation is intended; and aqueous and non-aqueous sterile suspensions which may contain suspending agents and thickeners. In some embodiments, the formulations of the subject matter of this disclosure include an adjuvant, optionally an oily adjuvant.

[0135] The compositions used in this method may take the form of suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain compounding agents such as suspending agents, stabilizers, and / or dispersants. The compositions used in this method may, but are not limited to, take the form of perioral, intravenous, intraperitoneal, intramuscular, and intratumoral formulations. Alternatively, or in addition, the active ingredient may be in powder form for preparation with a suitable vehicle (e.g., sterile water free of pyrogens) before use.

[0136] The formulation can be supplied in unit dose or multi-dose containers, such as sealed ampoules and vials, and can be stored frozen or freeze-dried, requiring only the addition of a sterile liquid carrier immediately before use.

[0137] For oral administration, the composition may take the form of tablets or capsules, prepared by common techniques using pharmaceutically acceptable additives such as binders (e.g., pregelatinized corn starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). Tablets may be coated by methods known in the art. For example, neurotropic steroids can be formulated in combination with hydrochlorothiazide as a pH-stabilized core having an enteric or delayed-release coating that protects the neurotropic steroid until it reaches the colon.

[0138] Liquid formulations for oral administration may take the form of solutions, syrups, or suspensions, or may be provided as dry products to be combined with water or other suitable vehicles before use. Such liquid formulations can be prepared by general techniques using pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives, or hydrogenated edible fats); emulsifiers (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl p-hydroxybenzoate, or sorbic acid). The formulations may also contain buffer salts, flavorings, colorings, and sweeteners as needed. Formulations for oral administration can be appropriately formulated to result in controlled release of the active compound. For buccal administration, the composition may take the form of tablets or lozenges formulated by general methods.

[0139] The compounds can also be formulated as implantable or injectable preparations. For example, the compounds can be formulated using suitable polymeric or hydrophobic materials (e.g., as emulsions in acceptable oils) or ion exchange resins, or as sparingly soluble derivatives (e.g., as sparingly soluble salts).

[0140] The compound can also be formulated in oil to be administered as a water-in-oil emulsion, an oil-in-water emulsion, or a water-in-oil emulsion.

[0141] The compounds can also be formulated into rectal compositions (e.g., suppositories or retained enemas containing common suppository bases such as cocoa butter or other glycerides), creams or lotions, or transdermal patches.

[0142] In some embodiments, the subject matter of this disclosure uses compositions that are pharmaceutically acceptable for human use. Those skilled in the art will understand the properties of components that may be present in compositions that are pharmaceutically acceptable for human use, and which components should be excluded from compositions that are pharmaceutically acceptable for human use.

[0143] Where used herein, the terms “therapeutic effective dose,” “therapeutic dose,” and “effective dose” are interchangeable and refer to a sufficient amount of the therapeutic composition to obtain a measurable response (e.g., a biological or clinically relevant response in the subject of treatment). The actual dose level of the active ingredient in the pharmaceutical compositions of the subject of this disclosure can be varied to administer an effective amount of the active compound to achieve a desired therapeutic response in a particular subject. The selected dose level may depend on the activity of the therapeutic composition, the route of administration, combination with other drugs or treatments, the severity of the condition being treated, the condition and prior medical history of the subject of treatment, etc. However, it is within the skill of those skilled in the art to start with a dose of the compound at a level lower than necessary to achieve the desired therapeutic effect and gradually increase the dose until the desired effect is achieved. The potency of the therapeutic composition may vary, and therefore the “therapeutic effective dose” may change. However, those skilled in the art can easily assess the potency and effectiveness of candidate modifiers of the subject of this disclosure and adjust the treatment plan accordingly.

[0144] After reviewing the subject matter disclosed herein, those skilled in the art can adjust the dosage to suit individual subjects, taking into account specific formulations, methods of administration used with compositions, and other factors. Further calculations of the dosage may take into account the subject's height and weight, the severity and stage of symptoms, and the presence of additional adverse health conditions. The evaluation of such adjustments or modifications, and when and how to make such adjustments or modifications, is well known to those skilled in the medical field.

[0145] Accordingly, in some embodiments, the term “effective dose” is used herein to refer to the amount of a composition comprising a drug that provides and / or induces a humoral or cellular immune response to a gastrin peptide, and / or inhibits the expression of a gastrin gene product, a pharmaceutically acceptable salt thereof, a derivative thereof, or a combination thereof, sufficient to produce measurable antitumor and / or anticancer bioactivity. The actual dose level of the active ingredient in the compositions of the subject of this disclosure can be modified to administer an amount of the active compound effective in achieving a desired response for a particular subject and / or use. The selected dose level may depend on a variety of factors, including the activity of the composition, the formulation, the route of administration, combination with other drugs or treatments, the severity of the condition being treated, the health status of the subject being treated, and their prior medical history. In some embodiments, a minimum dose is administered, and the dose is increased to a minimum effective dose in the absence of dose-limiting toxicity. Determining and adjusting the effective dose, and evaluating when and how to make such adjustments, is known to those skilled in the art.

[0146] In administering the compositions disclosed herein, a common method for estimating human dosages based on the doses administered to mouse animal models can be carried out using techniques known to those skilled in the art. In this method, drug doses can also be given in milligrams per square meter of body surface area, as this correlates well with predetermined metabolic and excretory functions rather than body weight. Furthermore, body surface area can be used as a common denominator for drug doses in adults and children, as well as in various animal species, as described in Freireich et al., 1966. Simply put, the mg / kg dose in any given species can be equivalent to mg / m². 2 To express it as a dose, multiply that dose by the appropriate km coefficient. For a human adult, 100 mg / kg is 100 mg / kg × 37 kg / m². 2 = 3700 mg / m² 2 It is equivalent to.

[0147] For additional guidance on prescription and dosage, see U.S. Patent No. 5326902; No. 5234933; PCT International Publication No. WO93 / 25521; Remington et al., 1975; Goodman et al., 1996; Berkow et al., 1997; Speight and Holdford, 1997; Ebadi, 1998; Duch et al., 1998; Katzung, 2001; Gerbino, 2005.

[0148] The compositions of this disclosure can be administered to a subject by any dosage form and / or any route of administration. In some embodiments, the formulation is a sustained-release formulation, a controlled-release formulation, or a formulation designed for both sustained-release and controlled-release. As used herein, the term “sustained-release” refers to the release of an active agent such that a nearly constant amount of the active agent becomes available to the subject over time. The term “controlled-release” is broader and refers to the release of an active agent over time, which may or may not be at a constant level. In particular, “controlled-release” encompasses situations and formulations in which the active ingredient is not necessarily released at a constant rate, but may include increasing the release over time, decreasing the release over time, and / or a constant release with one or more periods of increasing release, decreasing release, or a combination thereof. Thus, “sustained-release” is a form of “controlled-release,” but the latter also includes modes of delivery that utilize changes in the amount of active agent delivered at different times.

[0149] In some embodiments, sustained-release formulations, controlled-release formulations, or combinations thereof are selected from the group consisting of oral formulations, peroral formulations, buccal formulations, enteral formulations, pulmonary formulations, rectal formulations, vaginal formulations, nasal formulations, tongue formulations, sublingual formulations, intravenous formulations, intra-arterial formulations, intracardiac formulations, intramuscular formulations, intraperitoneal formulations, transdermal formulations, intracranial formulations, intradermal formulations, subcutaneous formulations, aerosolized formulations, ophthalmic formulations, implantable formulations, depot injection formulations, transdermal formulations, and combinations thereof. In some embodiments, the route of administration is selected from the group consisting of oral, peroral, buccal, enteral, pulmonary, rectal, vaginal, nasal, tongue, sublingual, intravenous, intra-arterial, intracardiac, intramuscular, intraperitoneal, transdermal, intracranial, intradermal, subcutaneous, ocular, via implant, and via depot injection. Where applicable, continuous infusion can enhance drug accumulation at the target site (see, for example, U.S. Patent No. 6180082). For information relating to transdermal formulations and methods of delivering compositions, see also U.S. Patents 3,598,122; 5016,652; 593,5975; 6106,856; 6162,459; 6495,605; and 6582,724; and U.S. Patent Application Publication 2006 / 0188558. In some embodiments, administration is made via a route selected from the group consisting of oral, intravenous, intraperitoneal, inhalation, and intratumor.

[0150] Specific modes of administration of the compositions of the subject matter of this disclosure, used in accordance with the methods disclosed herein, may depend on a variety of factors, but are not limited to, the formulation used, the severity of the condition being treated, whether the active agent in the composition (e.g., PAS) is intended to act locally or systemically, and the mechanisms of metabolism or removal of the active agent after administration.

[0151] VI. Method and Use In some embodiments, the subject matter of this disclosure includes the treatment of gastrin-related tumors and / or cancers, the manufacture of pharmaceuticals for the treatment of gastrin-related tumors and / or cancers, the inhibition of the growth of gastrin-related tumors and / or cancers, the induction and / or promotion of humoral and / or cellular immune responses against gastrin-related tumors and / or cancers, the sensitization of tumors and / or cancers in subjects to gastrin and / or CCK-B receptor signaling, the prevention, mitigation and / or elimination of tumor and / or cancer-related fibrosis formation, particularly in the context of pancreatic cancer; the prevention, mitigation and / or elimination of metastasis of gastrin-related tumors and / or cancers; and tumor infiltration CD8 in tumors and / or cancers. + Increased lymphocyte count; FoxP3 present in tumors and / or cancers + Reduction in the number of inhibitory T regulatory cells; and T in subjects responding to gastrin-related tumors and / or cancer. EMRA This relates to the use of pharmaceutical compositions in terms of various methods and / or uses related to increasing the number of cells. Each of these methods and / or uses is described in further detail below.

[0152] VI.A. Methods for treating gastrin-related tumors and / or cancers In some embodiments, the subject matter of the present disclosure relates to methods for treating gastrin-related tumors and / or cancer. In some embodiments, the method involves administering to a subject in need (e.g., a subject having gastrin-related tumors and / or cancer) an effective amount of a composition comprising: a first agent that induces and / or provides an active and / or passive humoral immune response to gastrin peptides and / or CCK-B receptors; and a second agent that induces and / or provides a cellular immune response against gastrin-related tumors or cancer. Accordingly, the methods of the present disclosure in some embodiments rely on the use of a pharmaceutical composition having one or more active agents that together provide two different immunotherapeutic activities: providing and / or inducing an active and / or passive humoral immune response to gastrin peptides and / or CCK-B receptors, and inducing and / or providing a cellular immune response against gastrin-related tumors and / or cancer.

[0153] With regard to providing and / or inducing active and / or passive humoral immune responses to gastrin peptides and / or CCK-B receptors, the first agent present in the pharmaceutically acceptable compositions of the subject matter of this disclosure is selected from the group consisting of gastrin peptides designed to induce an active humoral response to gastrin, and / or gastrin and / or CCK-B receptors, and in some embodiments, anti-gastrin antibodies and / or anti-CCK-R antibodies designed to provide a passive humoral response to CCK-B receptors present on gastrin-associated tumors and / or cancers. While we do not wish to be bound by any particular theory of action, active and / or passive humoral immune responses to gastrin peptides and / or CCK-B receptors are designed to partially or completely inhibit gastrin signaling in gastrin-associated tumors and / or cancers via the CCK-B receptor by reducing gastrin binding to the CCK-B receptor by decreasing the amount of circulating gastrin present in the target, and / or by interfering with gastrin binding to the CCK-B receptor using neutralizing and / or blocking antibodies.

[0154] Accordingly, in some embodiments, the first agent comprises a gastrin peptide, optionally comprising, essentially comprising, or comprising an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4), wherein the glutamic acid residue at amino acid position 1 of any of SEQ ID NOs: 1 to 4 is a pyroglutamic acid residue. In some embodiments, the gastrin peptide is conjugated in the pharmaceutical composition to an immunogenic carrier, optionally via a linker, and even more optionally via a linker comprising ε-maleimidocaproic acid N-hydroxysuccinate ester. Non-limiting examples of immunogenic carriers include diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin. The structure of the first drug is described in more detail here, but in some embodiments, the linker and gastrin peptide are separated by an amino acid spacer, which optionally has a length of 1 to 10 amino acids, and optionally has a length of 7 amino acids.

[0155] As those skilled in the art will understand from this disclosure, in some embodiments the pharmaceutical composition further comprises an adjuvant, optionally an oily adjuvant, to enhance the immunogenicity of gastrin peptides and / or gastrin peptide conjugates when an active anti-gastrin humoral immune response is desired.

[0156] In some embodiments, to induce a cellular immune response against gastrin-associated tumors or cancers, the methods of the subject matter of this disclosure utilize a pharmaceutical composition comprising CARs and / or CAR-T cells, where the CARs bind to TAAs, CAAs, or their epitopes. Exemplary TAAs / CAAs include, but are not limited to, claudin 18.2 (GENBANK® acceptance number NP_001002026.1; expressed in gastric and pancreatic cancers; for a discussion of anti-claudin 18.2CARs, see PCT International Patent Application Publication 2020 / 135674, U.S. Patent Application Publication 20180233511, and U.S. Patent No. 10377822), glypican-3 (GENBANK® acceptance number NP_001158089.1; expressed in liver cancer; anti-glypican-3). For a discussion of pican-3CAR, see U.S. Patent Publication Nos. 2017 / 0369561 and 2019 / 0046659), mesothelin (GENBANK® acceptance number NP_005814.2; expressed in pancreatic cancer; for a discussion of anti-mesotelin CAR, see U.S. Patent No. 9272002 and U.S. Patent Publication No. 2018 / 0244796), carcinoembryonic antigen (CEA; GENBANK® acceptance number Q13982-1; expressed in gastric cancer, colon cancer, and liver metastases; anti-CEA This includes CARs (see U.S. Patent Publication No. 2017 / 0145095), prostate stem cell antigen (PSCA; GENBANK® acceptance number NP_005663.2, expressed in pancreatic cancer; see U.S. Patent Publication No. 2020 / 0140520 for a discussion of anti-PSCA CARs), and CD70 antigen (GENBANK® acceptance number NP_001243.1, expressed by pancreatic cancer; see U.S. Patent Publication No. 2018 / 0230224 for a discussion of anti-CD70 CARs).CARs that bind to various TAAs and / or CAAs are marketed and / or under development by various sources, including CARsgen Therapeutics in Hsanghai, China (e.g., CARs targeting claudin 18.2 for gastric and pancreatic tumors and cancers), Kuur Therapeutics in Houston, Texas (e.g., CARs targeting glypican 3 for liver tumors and cancers), the University of Pennsylvania (e.g., CARs targeting mesothelin for pancreatic tumors and cancers), Sorrento Therapeutics in San Diego, California (e.g., CARs targeting CEA for gastric, colon, and pancreatic tumors and cancers, and liver metastases), Bellicum Pharmaceuticals in Houston, Texas (e.g., CARs targeting PSCA for pancreatic tumors and cancers), and the National Cancer Institute (NCI; e.g., CARs targeting CD70 for pancreatic tumors and cancers).

[0157] In some embodiments, the compositions and methods of the subject matter of this disclosure may utilize one or more checkpoint inhibitors. As is known, checkpoint inhibitors inhibit the biological activity of one or more target polypeptides having immune checkpoint activity. Exemplary such polypeptides include cytotoxic T lymphocyte antigen 4 (CTLA4) polypeptide, programmed cell death 1 receptor (PD-1) polypeptide, and programmed cell death 1 receptor ligand (PD-L1) polypeptide. In some embodiments, the checkpoint inhibitor includes an antibody or small molecule that binds and interferes with the interaction between T cells and tumor cells by inhibiting or preventing the interaction between PD-1 polypeptide and PD-L1 polypeptide. Examples of such antibodies and small molecules include, but are not limited to, ipilimumab, tremelimumab, nivolumab, pidilizumab, pembrolizumab, AMP514, AUNP12, BMS-936559 / MDX-1105, atezolizumab, MPDL3280A, RG7446, RO5541267, MEDI4736, avelumab, and durvalumab.

[0158] The pharmaceutical compositions of the subject matter of this disclosure may contain varying amounts of each active agent, provided that both humoral and cellular responses are induced and / or provided in the subject, and the amount of each agent present in the pharmaceutical composition may be adjusted to maximize therapeutic efficacy and / or minimize undesirable side effects of the treatment. However, in some embodiments, the pharmaceutical compositions of the subject matter of this disclosure are administered in doses selected from the group consisting of about 50 μg to about 1000 μg, about 50 μg to about 500 μg, about 100 μg to about 1000 μg, about 200 μg to about 1000 μg, and about 250 μg to about 500 μg, and optionally, the administration is repeated once, twice, or three times, and optionally, the second dose is administered one week after the first dose, and the third dose, if administered, is administered one or two weeks after the second dose.

[0159] In some embodiments, a method for treating gastrin-related tumors and / or cancers of the subject matter of this disclosure comprises administering to a subject in need a first agent that directly or indirectly inhibits one or more biological activities of gastrin in the tumor / or cancer, and a second agent that includes a stimulator of a cellular immune response against the tumor and / or cancer. In some embodiments, the first agent directly or indirectly inhibits one or more biological activities of gastrin in the tumor and / or cancer by providing and / or inducing a humoral immune response to gastrin peptides, and optionally, the agent is selected from the group consisting of anti-gastrin antibodies and gastrin peptides that induce the production of neutralizing anti-gastrin antibodies in the subject; and / or includes nucleic acids that inhibit the expression of gastrin gene products. Nucleic acids that inhibit the expression of gastrin gene products will be understood by those skilled in the art in light of this disclosure, and examples are discussed above. In some embodiments, the first agent facilitates access by tumors and / or cancer to the second agent, and in some embodiments, the second agent is, but not limited to, an antitumor and / or anticancer immunotherapy molecule, such as, but not limited to, CARs that bind to TAAs and / or CAAs, and / or CAR-T cells containing antitumor and / or anticancer CARs.

[0160] Antigastrin antibodies are known in the art and are described in U.S. Patents 5,607,676, 5,609,870, 5,622,702, 5,785,970, 5,866,128, and 6,861,510. See also PCT International Patent Application Publications 2003 / 005,955 and 2005 / 095,459. The contents of these U.S. patents and PCT International Patent Application Publications are incorporated herein by reference in their entirety. In some embodiments, the antigastrin antibody is an antibody against an epitope present in gastrin 17 (G17). In some embodiments, the epitope is present in one or more of the amino acid sequences EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4).

[0161] In some embodiments, administration of the pharmaceutical compositions of the subject matter of this disclosure to subjects induces a reduction in fibrosis associated with pancreatic cancer and / or prevents its development.

[0162] In some embodiments, the therapeutic methods of the present disclosure are designed to inhibit the growth and / or survival of gastrin-related tumors and / or cancers in a subject. Accordingly, in some embodiments, the methods of the present disclosure involve administering to a subject a composition comprising a first agent comprising a gastrin immunogen, one or more anti-gastrin antibodies, one or more anti-CCK-B receptor antibodies, or any combination thereof; and a second agent comprising a checkpoint inhibitor.

[0163] Accordingly, in some embodiments, the subject matter of the present disclosure provides the use of the pharmaceutical compositions disclosed herein for the preparation of pharmaceuticals for treating gastrin-related tumors and / or cancers, and the use of the pharmaceutical compositions disclosed herein for treating gastrin-related tumors and / or cancers.

[0164] In some embodiments, the multi-pharmaceutical compositions disclosed herein result in enhanced, more effective, and / or more successful treatment of gastrin-related tumors and / or cancers than treating similar targets individually with any of the agents.

[0165] VI.B. Methods for inducing and / or facilitating access to immunotherapy molecules to gastrin-related tumors and / or cancers PAS has been shown to alter the tumor microenvironment (TME) and make tumor-based therapies more responsive. PAS therapy reduces fibrosis, repolarizes tumor-associated macrophages from tumor-promoting (M2) macrophages to tumor-killing (M1) macrophages, and repolarizes tumor-infiltrating lymphocytes (CD8). + ) increases the number. The lack of effectiveness of CAR T cells in solid tumors has been suggested to be related to these characteristics of TMEs that hinder the influx of CAR T cells. We believe that adding PAS improves the penetration of CAR T cells and their effectiveness in treating solid tumors. We propose to investigate the role of PAS in promoting CAR T cell therapy in GI cancers, with a focus on pancreatic cancer.

[0166] Accordingly, in some embodiments, the subject matter of the present disclosure also provides methods for inducing and / or facilitating access of immunotherapy molecules to gastrin-related tumors and / or cancers in a subject. In some embodiments, the method comprises administering to a subject having a gastrin-related tumor or cancer an effective amount of a composition containing a drug that reduces or inhibits gastrin signaling via CCK-B receptors present on the gastrin-related tumor or cancer, thereby facilitating access of immunotherapy molecules to the gastrin-related tumor and / or cancer in the subject.

[0167] As used herein, the term “immunotherapy molecule” refers to any molecule that generates and / or contributes to an immune response sufficient to achieve at least one therapeutic effect in an individual. In some embodiments, the immunotherapy molecule is a molecule that binds to tumor and / or cancer-associated antigens and triggers an immune response against the tumor and / or cancer-associated antigens. In some embodiments, the immunotherapy molecule is a chimeric antigen receptor (CAR), which, in some embodiments, is present on the surface of CAR T cells.

[0168] Where used herein, the phrase "induces and / or promotes a cellular immune response against gastrin-related tumors and / or cancers" and its grammatical variations refer to a situation in which, as a result of administering an effective amount of a composition containing an agent that reduces or inhibits gastrin signaling via CCK-B receptors present on gastrin-related tumors or cancers to a subject having a gastrin-related tumor and / or cancer, the level of the T-cell-based immune response in the subject at the relevant time after administration is higher than would have been present in the subject without treatment. Agents that reduce or inhibit gastrin signaling via CCK-B receptors present on gastrin-related tumors or cancers include, but are not limited to, agents disclosed herein that can interfere with the interaction between gastrin peptides and CCK-B receptors, but also include gastrin peptides and / or immunogens, anti-gastrin antibodies, anti-CCK-B receptor antibodies, small molecule inhibitors of gastrin / CCK-B signaling, and combinations thereof.

[0169] In some embodiments, the subject matter of this disclosure also provides a method for sensitizing tumors and / or cancers in a subject that are associated with gastrin and / or CCK-B receptor signaling to an inducer of a cellular immune response against tumors and / or cancers. Where used herein, the phrase "sensitizing tumors and / or cancers in a subject that are associated with gastrin and / or CCK-B receptor signaling to an inducer of a cellular immune response" refers to a treatment that results in a level of cellular immune response in a subject when one or more inducers of a cellular immune response are administered to the subject, compared to the level of cellular immune response in a subject when one or more inducers of a cellular immune response are administered to the subject in the absence of treatment. In some embodiments, the inducer of a cellular immune response against tumors and / or cancers is a CAR, and optionally the CAR is present on CAR-T cells.

[0170] In some embodiments, the method involves administering to a subject a composition comprising a first agent that induces and / or provides an active and / or passive humoral immune response to a gastrin peptide, a second agent that induces and / or provides a cellular immune response to a tumor and / or cancer, or a combination thereof, wherein the first and second agents are optionally selected individually from the group consisting of gastrin peptides and / or fragments and / or derivatives thereof that induce a cellular immune response or the production of neutralizing anti-gastrin antibodies in the subject; and / or a composition comprising nucleic acids that inhibit the expression of gastrin gene products; and / or a composition comprising an agent that blocks the biological function of gastrin at the CCK-B receptor. In some embodiments, the anti-gastrin antibody is an antibody against an epitope present in gastrin 17 (G17).

[0171] Accordingly, in some embodiments, the method for sensitizing tumors and / or cancers associated with gastrin and / or CCK-B receptor signaling in a subject to an inducer of a cellular immune response involves administering the pharmaceutical compositions disclosed herein to the subject in order to provide both an active and / or passive humoral immune response to gastrin peptides in the subject, and to induce and / or provide a cellular immune response against tumors and / or cancers.

[0172] VI.C. Methods for preventing, reducing, and / or eliminating fibrosis associated with tumors and / or cancer. Various tumors and cancers, including solid tumors and pancreatic cancer, are also characterized by a dense fibrotic environment (Neesse et al., 2011), which promotes angiogenesis and creates a physical barrier that may inhibit the penetration of immunotherapy drugs into the tumor site (Templeton and Brentnall, 2013). Disclosed herein is the unexpected and surprising finding that administration of PAS in optional combination with one or more other antitumor and / or anticancer agents, including immune checkpoint inhibitors, can reduce the fibrotic nature characteristic of solid tumors (such as pancreatic cancer). While we do not wish to be bound by any particular theory of action, the reduction in fibrosis may promote better penetration of other active agents, including macromolecules such as CARs, CAR-T cells, and checkpoint mAbs. This partially explains why certain solid tumors and other cancers have historically been characterized by relative insensitivity to treatment with checkpoint inhibitors and other antitumor / anticancer therapies, likely due to insufficient penetration of immunotherapy molecules and / or checkpoint mAbs into tumor cells. Accordingly, one aspect of the subject matter of this disclosure is that PAS in combination with other antitumor / anticancer molecules (e.g., CARs, immune checkpoint inhibitors, etc.) have separate antitumor / anticancer activity when given as monotherapy, but they have far greater activity when given as combination therapy as disclosed herein.

[0173] To address the inherent fibrous nature of given tumors and cancers and to enable greater access for large therapeutic molecules (but not limited to monoclonal antibodies (mAbs), CARs, etc.) to the tumor environment, novel and innovative drug combinations with diverse but complementary or even synergistic mechanisms of action are provided in accordance with the subject matter of this disclosure. While we do not wish to be bound by any particular theory of action, when administered together as part of combination therapy, PAS and CAR (optionally combined with one or more immune checkpoint inhibitors) can produce a synergistic effect that makes it easier for chemotherapeutic agents such as CAR-T cells and / or immune checkpoint inhibitors to reach tumors and cancers by reducing tumor and / or cancer-associated fibrosis, enabling antitumor / anticancer agents (e.g., antitumor CAR-T cells) to induce a cellular immune response against gastrin-associated tumors.

[0174] Treatment with PAS induces a humoral immune response (i.e., an antibody response) to the autocrine and paracrine tumor / cancer growth factor gastrin. In this process, PAS influences the tumor / cancer phenotype by affecting cell proliferation, apoptosis, angiogenesis, invasion, and metastasis. As disclosed herein, PAS is also effective in reducing fibrosis associated with solid tumors, including, but not limited to, PDACs. While we do not wish to be bound by any specific theory of action, it is thought that this enhances the accessibility of larger molecules, such as, but not limited to, immunotherapy molecules (e.g., CARs and immune checkpoint inhibitor mAbs), to tumor sites, thereby promoting a greater cellular immune effect. PAS also elicits a cellular immune response to gastrin. Accordingly, disclosed herein are methods for treating tumors and / or cancers by administering PAS in combination with the administration of CARs, CAR-T cells, and / or immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and / or anti-CTLA-4 mAbs, in order to address the refractory nature of certain tumors and cancers that are resistant to therapeutic agents requiring access to the tumor and / or cancer for their inherent fibrosis and efficacy.

[0175] Accordingly, in some embodiments, the subject matter of the present disclosure provides methods for preventing, mitigating, and / or eliminating the formation of fibrosis associated with tumors and / or cancer, optionally pancreatic cancer and / or solid tumors, by contacting tumor and / or cancer cells with agents that directly or indirectly inhibit one or more biological activities of gastrin in tumors and / or cancer. Agents that directly or indirectly inhibit one or more biological activities of gastrin are disclosed herein and include agents that provide and / or induce a humoral immune response to gastrin peptides (but not limited to anti-gastrin antibodies and / or fragments and / or derivatives thereof), gastrin peptides that induce the production of neutralizing anti-gastrin antibodies in a subject; inhibitory nucleic acids that inhibit the expression of gastrin gene products; small molecule compounds that block the function of gastrin hormones, and any combination thereof. In some embodiments, the anti-gastrin antibody comprises an antibody against an epitope present in gastrin 17 (G17), the epitope being present in one or more of the amino acid sequences EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4).

[0176] As with other immunogenic forms of gastrin and gastrin peptides disclosed herein, in some embodiments, the gastrin peptide is conjugated to an immunogenic carrier, optionally selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin.

[0177] In some embodiments, a method for preventing, mitigating, and / or eliminating the formation of fibrosis associated with tumors and / or cancer, optionally solid tumors and / or pancreatic cancer, further comprises contacting the tumor and / or cancer with a second agent, which includes an immunotherapeutic agent such as CAR or CAR-T cells, or an agent that stimulates a cellular immune response against the tumor and / or cancer. Other exemplary stimulants of the cellular immune response that can be used in combination with the first agent and / or immunotherapy agent include, but are not limited to, ipilimumab, tremelimumab, nivolumab, pidilizumab, pembrolizumab, AMP514, AUNP12, BMS-936559 / MDX-1105, atezolizumab, MPDL3280A, RG7446, RO5541267, MEDI4736, and avelumab, which inhibit the biological activity of target polypeptides selected from the group consisting of cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 receptor (PD-1), and programmed cell death 1 receptor ligand (PD-L1).

[0178] In some embodiments, the tumor and / or cancer whose formation of fibrosis is prevented, mitigated, and / or eliminated is a solid tumor or pancreatic cancer.

[0179] In summary, in some embodiments, the subject matter of the present disclosure relates to the use of compositions of the present disclosure comprising a gastrin immunogen in association with an immunotherapy agent (e.g., in CAR and / or CAR-T cells, in combination with one or more immune checkpoint inhibitors) for treating gastrin-related tumors and / or cancer, either alone as a first-line treatment, in combination with any other first-line treatment, or in combination with any other treatment deemed appropriate for a subject having gastrin-related tumors and / or cancer.

[0180] VI.D. Methods for sensitizing solid tumors and / or cancers to chimeric antigen receptor-T (CAR-T) cell therapy In some embodiments, the subject matter of this disclosure also provides methods for sensitizing solid tumors and / or cancers in a subject to chimeric antigen receptor-T (CAR-T) cell therapy. As used herein, the phrase “sensitizing solid tumors and / or cancers to chimeric antigen receptor-T (CAR-T) cell therapy” refers to a treatment that, as a result of the treatment, makes the solid tumors and / or cancers more sensitive to CAR-T cell therapy compared to their sensitivity to CAR-T cell therapy as if there were no treatment. Without wishing to be bound by any particular theory of action, in some embodiments the treatment may result in greater accessibility of the tumor to CAR-T cell therapy, and in some embodiments, it may include reducing fibrosis or any other physical impairment to CAR-T cells invading the solid tumor.

[0181] Accordingly, in some embodiments, the method comprises sensitizing a solid tumor and / or cancer in a subject to CAR-T cell therapy by administering to the subject a first composition comprising, essentially, or consisting of a conjugate comprising, conjugated to, or optionally conjugated via, a gastrin immunogen conjugated to an immunogenic carrier and optionally conjugated via a linker, in an amount and route sufficient to promote the entry of CAR-T cells into a solid tumor and / or cancer; and administering to the subject a second composition comprising, essentially, or consisting of CAR-T cells targeted against antigens present in the solid tumor and / or cancer. As described herein, in some embodiments, the solid tumor and / or cancer is a solid gastrointestinal tumor and / or cancer, optionally a solid gastrin-dependent gastrointestinal tumor and / or cancer, and optionally a solid pancreatic tumor and / or cancer.

[0182] The methods of the present disclosure can also be used in the context of combination therapy, and in some embodiments, the methods further include administering one or more additional antitumor and / or anticancer therapies to the subject. The one or more additional antitumor and / or anticancer therapies may be additional antitumor and / or anticancer therapies appropriate to the type of tumor and / or cancer being treated with CAR-T cell therapy. Thus, the one or more additional antitumor and / or anticancer therapies, in some embodiments, but not limited to, include, essentially, or may involve administering an immune checkpoint inhibitor (CPI) to the subject, such as a cytotoxic T lymphocyte antigen 4 (CTLA4) inhibitor, a programmed cell death 1 receptor (PD-1) inhibitor, a programmed cell death 1 receptor ligand (PD-L1) inhibitor, or any combination thereof. Examples of CPIs include, but are not limited to, ipilimumab, tremelimumab, nivolumab, pidilizumab, pembrolizumab, AMP514, AUNP12, BMS-936559 / MDX-1105, atezolizumab, MPDL3280A, RG7446, RO5541267, MEDI4736, and avelumab.

[0183] As a result of sensitizing solid tumors and / or cancers in a subject to chimeric antigen receptor-T (CAR-T) cell therapy, the method of the present disclosure reduces and / or inhibits the growth of tumors and / or cancers in the subject compared to what would have occurred if the first composition had not been administered.

[0184] VII. Conclusion Accordingly, the subject matter of this disclosure relates to combination therapies for the treatment of cancer that, in some embodiments, use combinations of methods for individually or together generating both humoral antibody immune responses (e.g., using gastrin cancer vaccine PAS) and cellular immune responses (e.g., using CARs that bind to gastrin cancer vaccine PAS, TAA and / or CAA, optionally CARs present on CAR-T cells, and optionally in combination with immune checkpoint inhibitors). More specifically, unexpected additive and / or synergistic efficacy in the treatment of human and animal gastrointestinal tumors is described using the described combinations of drug classes that generate humoral and cellular immune antitumor responses in combination with cellular immune antitumor effects.

[0185] More specifically, the subject matter of the present disclosure relates to the use of specific combinations of drugs (e.g., using CARs and / or CAR-T cells, optionally in combination with one or more CPIs) that, in some embodiments, (i) induce a humoral B-cell immune response to tumor growth factors or circulating tumor growth factors (e.g., gastrin immunogens such as POAS, but not limited to them); and (ii) induce and / or promote a cellular immune response against tumors and / or cancer (i.e., an antitumor and / or cancer T-cell response) to induce a cytotoxic T lymphocyte response.

[0186] Thus, in some embodiments, disclosed herein are methods for treating human and animal tumors and cancers using a gastrin cancer vaccine combined with a second active agent that overcomes tumor immunity, particularly tumor immunity against antitumor T-cell immune responses, and a combination of one or more further active agents that optionally overcome immune checkpoint failure. Accordingly, in some embodiments, the subject matter of this disclosure relates to treating specific human cancers using cancer vaccines directed to induce B-cell and / or antibody immune responses, as well as cellular immune responses against the growth factor gastrin and / or other TAAs and / or CAAs, the vaccine therapy also makes tumors more responsive to CAR, CAR-T cell therapy, and in some embodiments more responsive to immune checkpoint inhibitors, thus producing unexpected additive or even synergistic combination therapeutic effects that enhance the antitumor effect.

[0187] In addition, the pharmaceutical compositions of the subject matter of this disclosure, in some embodiments, are CAR-T cells containing CARs that bind to TAAs and / or CAAs expressed by the tumor and / or cancer being treated, and CD8 + The pharmaceutical composition disclosed herein can be used to prevent, mitigate, and / or eliminate metastasis of gastrin-related tumors or cancer by administering to a subject having a gastrin-related tumor or cancer in an amount sufficient to enhance the number of tumor-infiltrating lymphocytes (TILs).

[0188] With respect to compositions and methods of the subject matter of this disclosure, in some embodiments, administration improves the survival of the subject, reduces tumor growth, and / or enhances the effectiveness of chemotherapeutic agents and / or immune checkpoint therapies in the subject, compared to what would occur if the pharmaceutical composition were not administered. [Examples]

[0189] Materials and methods for the examples The following embodiments provide illustrative examples. Given the present disclosure and the general level of those skilled in the art, those skilled in the art will understand that the following embodiments are intended for illustrative purposes only and that many variations, modifications, and changes can be adopted without departing from the scope of the subject matter of the present disclosure.

[0190] Cell lines. Two mouse cell lines were evaluated in this study. The mouse gastric cancer cell line NCC-S1 (NCC; Park et al., 2015) was provided by Dr. Kim through Dr. Timothy Wang of Columbia University (New York, New York, United States of America), a collaborator. These gastric cancer cells have been shown to be metastatic when grown orthotopic in a syngeneic mouse model. The second gastric cancer cell line, YTN-16 (YTN), was established by Professor Sachiyo Nomura (Yamamoto et al., 2018) and provided through her collaborator, Dr. James R. Goldenring of Vanderbilt University School of Medicine (Nashville, Tennessee, United States of America). YTN cells are known to be invasive and metastatic even after subcutaneous injection into mice. Before use in animals, the cells were examined by IMPACT II PCR profiling and were negative for all pathogens. YTN cells were cultured using DMEM, and NCC cells were cultured in RPMI medium; both were grown in a humidified 5% CO2 incubator at 37°C with 10% fetal bovine serum.

[0191] Characterization of cell lines and receptors by real-time PCR. Total RNA was extracted from cells (Qiagen) and subjected to qRT-PCR in high-speed cycle mode using a thermal cycler (Applied Biosystems) to examine cholecystokinin B receptor (CCK-BR) expression and PD-L1 expression. The primers used included the following: CCK-BR forward: 5'-GATGGCTGCTACGTGCAACT-3' (Sequence ID: 7) CCK-BR reverse direction: 5'-CGCACCACCCGCTTCTTAG-3' (Sequence ID: 8) PD-L1 forward direction: 5'-TGCGGACTACAAGCGAATCACG-3' (Sequence ID: 9) PD-L1 reverse direction: 5'-CTCAGCTTCTGGATAACCCTCG-3' (Sequence ID: 10) qRT-PCR was set to fast cycle mode (primer Tm > 60°C). HPRT was used as the normalizer control gene. Since neither CCK-BR nor PD-L1 are expressed, the control RNA was extracted from mouse liver.

[0192] In vivo animal studies. All animal studies were conducted ethically under the approval of the Institutional Animal Care and Use Committee (IACUC) at Georgetown University (Washington DC, United States of America). Several attempts were made to establish tumors in C57BL / 6 mice using NCC cells. The first attempt involved 5 × 10⁶ cells with luciferase tags. 5 NCC cancer cells were injected orthotopically into the gastric subserosa (n=40). After imaging with luciferin and dissection of the mice, no tumors were found. Next, NCC cells were injected into the right flank in a total volume of 0.1 mL, 1.5 × 10⁴. 6 NCC cancer cells were injected subcutaneously, but no tumors formed even after 33 days. YTN(5×10 6 YTN cells were injected into each of 40 female C57BL / 6 mice at a volume of 0.2 mL. YTN cells are known to be invasive and metastatic even after subcutaneous injection into mice (Yamamoto et al., 2018). Tumor growth was measured weekly with calipers, and the volume was calculated as L × W² × 0.5.

[0193] Treatment. Mice were divided into four treatment groups (n=10 each). Control mice were treated with intraperitoneal injection of 0.1 mL of PBS concurrently with other treatments. 50 μg of PD-1 antibody (PD-1 Ab; clone RMPI-14 purchased from BioX Cell (West Lebanon, New Hampshire, United States of America)) was administered intraperitoneally at baseline (1 week after tumor inoculation; week 0) and at weeks 1, 3, and 6. 250 μg of PAS was administered subcutaneously in 0.1 mL volume concurrently with PD-1 Ab and again at week 9. After 10 weeks of growth, the control mice appeared to be in a mortal state, so the mice were ethically euthanized, the tumors were excised, weighed, and metastases were counted.

[0194] Histological analysis. All observed and counted metastases were dissected, fixed in formalin for confirmation by hematoxylin and eosin (H&E) staining, and embedded in paraffin. To analyze fibrosis in the tumor microenvironment, the tumors were reacted with Masson's trichrome staining. To quantify the tumor growth index, tissue sections (5 μm) were reacted with rabbit monoclonal antibody against Ki67 (catalog number CRM325; Biocare Medical, Pacheco, California, United States of America; 1:80 dilution). Immunohistochemical staining was also performed on tumor tissue sections (5 μm) using a rabbit polyclonal antibody against arginase-1 (catalog number PA5-29645; ThermoFisher Scientific, Waltham, Massachusetts, United States of America; 1:1800 dilution) to evaluate tumor-infiltrating lymphocytes using CD8 (catalog number 98941; Cell Signaling Technology, Danvers, Massachusetts, United States of America; 1:25 dilution) and to examine M2-polarized tumor-associated macrophages.

[0195] Statistical analysis. Linear regression analysis was used to analyze tumor growth rates and compare the slopes of growth curves between each treatment group. Slides were scanned using an Aperio GT450 instrument, and images were analyzed using Aperio Image Scope software for the number of immunoreactive cells per high-magnification field of view (for Ki67 and CD8 cells). Images of the same magnification and surface area were acquired for each tumor using Aperio software (maximum N=10 per slide), and fibrosis and M2-polarized macrophage integration density were analyzed using ImageJ computer software. Raw data from the images were analyzed using ANOVA and t-tests (with Bonferroni correction for multiple comparisons with controls) using GraphPad Prism version 9.

[0196] Example 1 Promoting tumor accessibility to immunotherapy Subjects with solid tumors that are refractory to antitumor immunotherapy are identified because, optionally, due to the presence of fibrosis in the solid tumor, the antitumor immunotherapy agent may not be able to reach the tumor microenvironment. A first composition, comprising, or essentially, a conjugate comprising, or conjugate comprising, an immunogenic carrier, optionally via a linker, is administered to the subject in an amount and route sufficient to promote the entry of antitumor T cells into the tumor. Administration of the first composition is repeated one or more times, if necessary, until fibrosis is reduced to a degree sufficient to increase access of CARs and / or CAR-T cells to the tumor. Then, a second composition, comprising, or essentially comprising, or conjugate comprising CARs and / or CAR-T cells that bind to TAAs present on the solid tumor, is administered to the subject on one or more occasions in an amount and route sufficient to allow the tumor to reach the CARs and / or CAR-T cells, thereby inducing an immune response against the tumor in the subject, and thereby treating the solid tumor in the subject. Additional administrations of the first composition and / or the second composition are performed as necessary to treat solid tumors in the subject.

[0197] Example 2 Characterization of gastric cancer cells based on CCK-BR and PD-L1 receptors Two distinct mouse gastric cancer cells were evaluated in vitro for the expression of CCK-BR, PD-L1 receptor, and gastrin peptides. Gene expression of CCK-BR and PD-L1 was increased in both NCC and YTN gastric cancer cells compared to non-cancerous mouse tissue (Figure 1). CCK-BR expression increased more than 60-fold in mouse YTN and NCC gastric cancer cells compared to normal mouse tissue (Figure 1A). PD-L1 mRNA expression increased 52-fold in YTN cells and 24-fold in NCC cells compared to normal tissue (Figure 1B). Exposure to exogenous gastrin significantly increased the proliferation of NCC cells (p=0.004) (Figure 1C). Immunocytochemistry revealed the expression of endogenous gastrin peptides in both NCC (Figure 1D) and YTN (Figure 1E) gastric cancer cells, suggesting that these gastric cancer cells produce their own gastrin peptides to stimulate proliferation via CCK-BR in an autocrine manner. Control cells that reacted only with the secondary antibody were negative for staining (Figure 1F).

[0198] Example 3 The effects of PAS and PD-1 on the proliferation and metastasis of YTN tumors Figure 2A shows the tumor volume of YTN gastric cancer measured over time. Treatment with PD-1 Ab monotherapy had no effect on tumor growth compared to the control group. In contrast, in mice treated with PAS monotherapy or PAS and PD-1 Ab in combination, tumor growth was significantly delayed over time. PAS monotherapy delayed tumor growth by 31% compared to the PBS-treated control group (p=0.023). When PAS was administered in combination with PD-1 Ab, tumor growth was delayed by 59% compared to tumors in the PBS-treated control group (P=0.0003). When the tumor growth rate of PAS-vaccinated mice was compared to that of mice treated with combination therapy, the difference was statistically significant (p=0.0018). These results suggest that combination therapy is superior to PAS monotherapy. The tumor mass at resection was smaller in PAS and combination-treated mice, but this difference was not statistically significant (Figure 2B). The total number of metastases in each group was counted at autopsy and confirmed by histological examination. Figure 2C shows the noteworthy finding that there were no metastases in mice treated with the patent-pending monotherapy or PAS in combination with PD-1 Ab. Hematoxylin and eosin staining confirmed that the tissues excised from control mice and PD-1 Ab-treated mice were metastases. Figures 2D-2G show representative histological images of YTN metastases from the gastric wall, mesentery, peritoneum, and abdominal wall, respectively.

[0199] Another demonstration of the effect on tumor growth is the measurement of the Ki67 growth index. Ki67 immunoreactivity was increased in tumors of mice treated with PBS and PD-1 Ab (Figure 3A). In tumors of mice treated with PAS monotherapy or in combination with PD-1 Ab, the growth index was significantly reduced (Figure 3A). Representative low-magnification (2X) images of each treatment group are shown in Figure 3B, along with high-magnification (40X) inset images of each tumor. Significant Ki67 immunoreactivity is identified in tumors of mice treated with PBS and PD-1 Ab. In contrast, Ki67 staining is significantly reduced in tumors of mice treated with PAS, with or without PD-1 Ab. These tissue sections support the conclusion that tumors in PAS and combination-treated mice showed reduced growth or developmental rates.

[0200] Example 4 Combination therapy with PAS and PD-1 Ab reduces fibrosis in gastric cancer. Tumor fibrosis is thought to hinder the penetration of chemotherapeutic agents into the cancer and limit the influx of T lymphocytes. YTN gastric tumors exhibit characteristic dense fibrosis, as seen in the tumors of PBS-treated control mice with Masson's trichrome staining in Figure 3C. Fibrosis is significantly reduced in tumors of mice treated with PAS monotherapy or PAS in combination with PD-1 Ab. Computer analysis and quantitative determination of the integrated density of fibrosis for each treatment group are shown in Figure 3D. Fibrosis was slightly reduced in tumors of PD-1 Ab-treated mice, but the amount of fibrosis was even more significantly reduced when combined with PAS treatment.

[0201] Example 5 Combination therapy with PAS and PD-1 Ab alters the immune cell signature of gastric cancer. One reason for the lack of effectiveness of immune checkpoint therapy in cancer is thought to be the absence of tumor-infiltrating T cells. The tumors in each treatment group were identified by CD8 + T lymphocytes were stained, and the number of immunoreactive cells was compared between the groups. Figure 4A shows CD8 in gastric tumors of PBS control mice and PD-1 Ab-treated mice. + This indicates a deficiency of T cells. The number of CD8 immunoreactive cells is noticeably increased in tumors of PAS-treated mice and mice treated with combination therapy (Figure 4A). Computational analysis of YTN tumors stained with CD8 antibody showed that CD8 cells were present in tumors of PAS-treated mice. + Significant increase in T lymphocytes, and furthermore, CD8 in mice treated with combination therapy. + A significantly greater increase in T cells is also shown (Figure 4B).

[0202] Tumors in each group were also subjected to immunohistochemical staining using antibodies against arginase to detect M2-polarized tumor-associated macrophages (TAMs). These immunosuppressive TAMs were abundant in the tumors of control mice and PD-1 Ab-treated mice (Figure 4C). In contrast, gastric tumors in mice treated with PAS in combination therapy showed an abundance of arginase +TAMS levels are significantly lower. Computational analysis of integrated image density (Figure 4D) confirms a marked reduction in immunoreactivity in tumors from PAS-treated mice. In tumors from mice treated with both PAS and PD-1 Ab, immunoreactivity of arginase-positive TAMs is further reduced (Figure 4D).

[0203] Example 6 Immunohistochemistry reveals that human gastric cancer expresses CCK-BR. Human gastric cancer epithelial cells were positive for CCK-BR immunoreactivity (Figures 5A-5H). This means that administration of PAS to human subjects also reduces the activation of this receptor by neutralizing gastrin. The most common histological classification is described in Lauren, 1965, where cancer is histologically classified into one of two types: intestinal or diffuse. Figures 5A-5C show CCK-BR immunoreactivity in tissue from a human gastric cancer array with an intestinal-type histological appearance showing characteristic glandular or tubular lines by epithelial cells. Histologically, diffuse gastric cancer cells lack cohesiveness and invade tissue independently or in small clusters (Correa, 2013). Representative diffuse gastric cancer also shows CCK-BR expression, as shown in Figures 5D and 5E. Mucinous gastric cancer (Figure 5F) and signet ring gastric cancer (Figure 5G) are less common histological types of gastric cancer. Characteristic staining of CCK-BR-positive cells in normal human gastric glands is shown in Figure 5H. There were no significant differences in the intensity of CCK-BR staining, as analyzed by ImageJ, among tumors classified as Grade 1 (164.8±1.4), Grade 2 (159.7±1.4), and Grade 3 (162.8±1.1).

[0204] Consideration of the Examples Disclosed herein is evidence, using two mouse gastric cancer cell lines and human tissue microarrays, that the gastrin:CCK-BR signaling pathway is important for stimulating gastric cancer growth. CCK-BR was expressed in both cell lines, and exogenous gastrin stimulated cell growth in vitro, confirming gastrin sensitivity. Immunocytochemistry revealed endogenous gastrin expression within gastric cancer cells, suggesting that gastric cancer may regulate its own growth through an autocrine mechanism. Since exogenously administered gastrin, or gastrin endogenously produced by cancer cells, can activate the CCK-BR receptor and induce cell or tumor growth, strategies to block gastrin interactions should inhibit growth. Indeed, gastrin-targeting vaccines have been shown to inhibit the growth of mouse gastric cancer and prevent metastasis. Administration of a PAS vaccine as monotherapy reduced tumor growth in mice; however, the tumor inhibitory effect was significantly affected by co-administration of PD-1 Ab and PAS. A clear advantage of having therapeutic agents like the PAS vaccine that demonstrate efficacy as monotherapy is that, when treating patients with gastric cancer, not all patients are necessarily eligible for immune checkpoint antibody therapy, or some patients may experience side effects from immune checkpoint therapy; therefore, monotherapy can provide an alternative option for treating these patients. However, in patients eligible for immune checkpoint therapy, the additional patent application suggests that tumor growth may be significantly reduced and metastasis may be prevented. This vaccine, PAS, significantly reduced gastric cancer growth, and this change was histologically confirmed by a significant decrease in the number of Ki67 immunoreactive tumor cells. PAS therapy also reduced fibrosis in the tumor microenvironment. PAS vaccination also reduced CD8 + By increasing the number of T cells and decreasing the number of M2-polarized immunosuppressive macrophages, the tumor immune cell signature was altered, making the tumor microenvironment more sensitive to other therapies such as PD-1 Ab therapy.

[0205] Although cancer cells expressed PD-L1 receptors, PD-1 Ab monotherapy did not significantly reduce gastric cancer growth or metastasis. However, when PD-1 Ab therapy was administered in combination with PAS, it had a greater effect on tumor growth rate than PAS therapy alone. One explanation for the enhanced effect of PAS with PD-1 Ab is the CD8 markers when the two immunotherapies are administered together. + This is thought to be due to a significant increase in T cells. Another beneficial finding of combination therapy is the additive effect observed in the number of arginase-positive M2 polarized macrophages. We previously described an additive effect on tumor inhibition in pancreatic cancer, where PD-1 Ab therapy alone did not have a tumor inhibitory effect, but when combined with PAS, PD-1 Ab was more effective than PAS alone (Osborne et al., 2019a). In previous studies on pancreatic tumors, we also showed that PAS combined with PD-1 Ab reduced fibrosis in the tumor microenvironment. This reduction in fibrosis is expected to promote T cell influx.

[0206] The experiments disclosed herein were performed in immunocompetent mice carrying syngeneic mouse tumors, but the results of the CCK-BR immunoreactivity to human gastric cancer arrays support the important translational and clinical relevance of this study. Both mouse gastric cancers (YTN and NCC) expressed CCK-BR, and treatment of YTN tumor-bearing mice with a gastrin vaccine was found to significantly reduce tumor growth and metastasis. Gastrin is the primary ligand that activates CCK-BR, and since PAS therapy induces neutralizing gastrin antibodies and gastrin-activated memory T cells (Osborne et al., 2019a), the ability to reduce signaling at this receptor is central to inhibiting cancer growth. Sheng et al., 2020 demonstrated that mature enterochromaffin cell-like (ECL) cells in the gastric body express CCK-BR, and that gastric isthmus progenitor cells also express CCK-BR, which responds to hypergastrinemia by supplying new ECL cells. Their sophisticated research supports the importance of gastrin as a nutrient peptide that activates CCK-BR in the gastric mucosa. We previously showed that CCK-BR is expressed in several human gastric cancer cell lines (Smith et al., 1998) and that gastrin-stimulated proliferation in vitro was blocked only by the selective CCK-BR antagonist L265260. The immunoreactivity of human gastric cancer tissue arrays to CCK-BR in numerous human gastric cancers in this current study suggests the importance of this receptor as a potential therapeutic target in human subjects. The discovery of CCK-BR staining in both intestinal and diffuse histological gastric cancer types suggests broad implications for utilizing therapies that target this proliferation pathway. Although mucinous and signet-ring histological types occur less frequently, the prognosis in these histological types is typically more severe (Taghavi et al., 2012). Tissues in human gastric cancer arrays with these less frequent histological types also stain positively for CCK-BR, suggesting the potential for broad application of PAS therapy in gastric cancer.

[0207] Research into gastrin as an immunogen was initiated in the early 1990s by Dr. Susan Watson (Watson et al., 1996; Watson et al., 1999a; Watson et al., 1999b). Although not popular at the time, Dr. Watson decided to employ an immunological approach to the treatment of GI cancer by producing a high-affinity anti-G17 antibody that could neutralize serum gastrin and cell-associated gastrin. Since elevated serum gastrin levels had been previously reported in colorectal tumors (Smith et al., 1989), she decided to begin investigating these tumors (Watson et al., 1995; Watson et al., 1996). Over the years, a wealth of clinical data has been generated focusing on the appropriate adjuvants, administration schedules, dose concentrations, and boosters required to produce high-affinity anti-G17 antibodies. It was found that serum gastrin levels decreased as antibody titers increased (Rocha-Lima et al., 2014). Antibody titers could be tracked, and it was found that patients with titers 1.2 units higher than baseline had, on average, twice the survival time in colon, pancreatic, and gastric cancers. There were several surprising results in the process. First, PAS had a synergistic effect with gemcitabine; and second, unexpected long-term survivors were observed in several studies, including pancreatic cancer. These results lead to the discussion that something more than just neutralizing gastrin was probably happening; however, the tools available today were not available at the time. Although positive studies were conducted for all three indications and the product's safety profile was well characterized, the development of PAS was forced to take a major setback when the company that funded its development went bankrupt. The last patient treated with PAS was in 2004.

[0208] Over the past two years, much has been learned about the mechanism of action of PAS. PAS not only produces high-affinity anti-G17 antibodies but also activates cellular immune responses by increasing memory T cells, NKT cells, and gamma delta cells (Osborne et al., 2019a). Furthermore, it consistently alters the microenvironment in several animal models (pancreas and stomach), resulting in synergistic effects with checkpoint inhibitors (Osborne et al., 2019a). The prevention of metastasis in mice treated with PAS (Osborne et al., 2019b) is due to the inhibition of epithelial-mesenchymal transition, a mechanism that may help explain the long-term survival cases previously observed in clinical programs. The observed reduction in fibrosis with the patent-pending treatment may help explain the synergistic effects previously found with gemcitabine. PAS vaccination in a precancerous KRAS mouse model demonstrated that PAS not only reduces pancreatic fibrosis and alters the immune cell signature of the tumor microenvironment, but also reduces the proliferation and progression of precancerous PanIN lesions that prevent pancreatic cancer (Smith et al., 2021). These data are compelling for a better understanding of how to use PAS and bring it back into clinical practice.

[0209] References All references listed in this disclosure, including, but not limited to, all patents, patent applications and their publications, scientific journal articles, and database entries (including, but not limited to, GENBANK® biological sequence database entries and all annotations available therein), are incorporated herein by attribution to the extent that they supplement, explain, provide background to, and / or teach the methodologies, techniques, and / or compositions used herein. The review of the references is intended merely to summarize the claims made by their authors. No reference (or any part of any reference) is considered to be relevant prior art. The applicant reserves the right to challenge the accuracy and appropriateness of any cited reference.

[0210] Adams et al. (1993) Cancer Res 53:4026-4034. Alt et al. (1999) FEBS Lett 454:90-94. Berkow et al. (1997) The Merck Manual of Medical Information, edited by Home, Merck Research Laboratories, Whitehouse Station, New Jersey, United States of America. Bird et al. (1988) Science 242:423-426. Clackson et al. (1991) Nature 352:624-628. Coloma et al. (1997) Nature Biotechnol 15:159-163. Correa (2013) Gastroenterol Clin North Am 42:211-217. Duch et al. (1998) Toxicol Lett 100-101:255-263. Ebadi (1998) CRC Desk Reference of Clinical Pharmacology. CRC Press, Boca Raton, Florida, United States of America. Freireich et al. (1966) Cancer Chemother Rep 50:219-244. GENBANK (registered trademark) acceptance numbers AAA52771.1;NM_000805.5;NP_000725.1;NP_000796.1;NP_001002026.1;NP_001139345.1;NP_001158089.1;NP_001106862.1;NP_001230007.1;NP_001243.1;NP_005663.2;NP_005814.2;NP_006130.1;NP_031668.3;NP_741969.1;and Q13982-1. Gerbino(2005)Remington:The Science and Practice of Pharmacy.21st Edition, Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, United States of America。 Glockshuber et al. (1990) Biochemistry 29:1362-1367。 Goodman et al. (1996) Goodman & Gilman’s the Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill Health Professions Division, New York, New York, United States of America。 Halland et al. (2020) J Clin Invest 130:2673-2688。 Holliger et al. (1993) Proc Natl Acad Sci USA 90:6444-6448。 Hu et al. (1996) Cancer Res 56:3055-3061。 Huston et al. (1988) Proc Natl Acad Sci USA 85:5879-5883。 Huston et al. (1993) Int Rev Immunol 10:195-217。 Katzung(2001)Basic & Clinical Pharmacology, 8th Edition, Lange Medical Books / McGraw-Hill Medical Pub.Division, New York, New York, United States of America。 Kipriyanov et al. (1995) Cell Biophys 26:187-204。 Kipriyanov et al. (1998) Int J Cancer 77:763-772。 Kipriyanov et al. (1999) J Mol Biol 293:41-56。 Kohler et al. (1975) Nature 256:495. Kontermann et al. (1999) J Immunol Meth 226:179-188. Kortt et al. (1997) Protein Eng 10:423-433. Kostelny et al. (1992), J lmmunol 148:1547-1553. Kurucz et al. (1995) J Immunol 154:4576-4582. Lauren (1965) Acta Pathol Microbiol Scand 64:31-49. Le Gall et al (1999) FEBS Lett 453:164-168. Marks et al. (1991) J Mol Biol 222:581-597. McCartney et al. (1995) Protein Eng 8:301-314. Muller et al. (1998) FEBS Lett 432:45-49. Neesse (2013) Onco Targets Ther 7:33–43. Osborne et al (2019a) Cancer Immunol Immunother 68:1635-1648. Osborne et al (2019b) Am J Physiol Gastrointest Liver Physiol 317:G682-G693. Pack et al. (1992) Biochemistry 31:1579-1584. Park et al (2015) Mol Carcinog 54:1521-1527. Patel et al. (1999) Gene Therapy 6:412-419. PCT International Patent Application No. 1992 / 22653, International Publication No. 93 / 25521, International Publication No. 2003 / 005955, International Publication No. 2005 / 095459, International Publication No. 2020 / 135674. Pegram et al. (2012) Blood 119:4133-4141. Rehfeld et al. (1989) Cancer Res 49:2840-2843. Remington et al. (1975) Remington's Pharmaceutical Sciences, 15th edition, Mack Pub. Co., Easton, Pennsylvania, United States of America. Rocha-Lima et al. (2014) Cancer Chemother Pharmacol 74:479-486. Sadelain et al. (2009) Curr Opin Immunol 21:215-223. Segal et al (2014) J Clin Oncol 32(5s):abstr 3002. Shalaby et al. (1992) J Exp Med 175:217-225. Sheng et al (2020) Cell Mol Gastroenterol Hepatol 10:434-449. Singh et al (1986) Cancer Res 46:1612-1616. Smith and Solomon (1988) Gastroenterology 95:1541-1548. Smith et al. (1989) Dig Dis Sci 34:171-174. Smith et al. (1990) Dig Dis Sci 35:1377-1384. Smith et al. (1991) Regul Pept 32:341-349. Smith et al. (1995) Am J Physiol 268:R135-R141. Smith et al. (1996) Am J Physiol 271:R797-R805. Smith et al. (1998) Int J Oncol 12:411-419. Smith et al (2021) Cancer Prev Res (Phila) 14(10):933-944. Speight and Holford (eds.) (1997) Avery's Drug Treatment: A Guide to the Properties, Choice, Therapeutic Use and Economic Value of Drugs in Disease Management, 4th edition, Adis International, Philadelphia, Pennsylvania, United States of America. Stephan et al (2007) Nat Med 13:1440-1449. Taghavi et al. (2012) J Clin Oncol 30:3493-3498. Templeton and Brentnall (2013) Surgical Clinics of North America 93(3):629-645. U.S. Patent and Trademark Office (IPO) filings No. 2006 / 0188558, No. 2007 / 0036773, No. 2009 / 0180989, No. 2009 / 0257991, No. 2011 / 0038836, No. 2012 / 0058051, No. 2012 / 0213783, No. 2012 / 0252742, No. 2017 / 0145095, No. 2017 / 0369561, No. 2018 / 0230224, No. 2018 / 0244796, No. 2019 / 0046659, and No. 2020 / 0140520. U.S. Patent Nos. 3598122, 4816567, 5016652, 5234933, 5234933, 5326902, 5326902, 5607676, 5609870, 5622702, 5785970, 5866128, 5935975, 6106856, 6162459, 6172197, and 61800 No. 82; No. 6248516; No. 6291158; No. 6410319; No. 6495605; No. 6582724; No. 6861510; No. 8389282; No. 8802374; No. 9 No. 272002; No. 9988452; No. 10059923; No. 10113003; No. 10183992; No. 10301391; No. 10358492; and No. 10377822. Upp et al. (1989) Cancer Res 49:488-492. Watson et al. (1989) Br J Cancer 59:554-558. Watson et al. (1995) Int J Cancer 61:233-240. Watson et al. (1996) Cancer Res 56:880-885. Watson et al. (1998) Int J Cancer 75:873-877. Watson et al. (1999a) Int J Cancer 81:248-254. Watson et al. (1999b) Gut 45:812-817. Watson et al. (2006) Nature Reviews Cancer 6:936-946. Whitlow et al. (1991) Methods Companion Methods Enzymol 2:97-105. Yamamoto et al. (2018) Cancer Sci 109:1480-1492. Zhu et al. (1997) Protein Sci 6:781-788.

[0211] It will be understood that various details of the subject matter of this disclosure may be changed without departing from the scope of the subject matter of this disclosure. Furthermore, the foregoing explanation is for illustrative purposes only and not intended to limit the scope.

Claims

1. A composition for use in promoting anti-tumor or anti-cancer immunotherapy, comprising a conjugate comprising, consisting essentially of, or consisting of a gastrin immunogen conjugated to an immunogenic carrier.

2. The composition for use according to claim 1 , wherein the gastrin immunogen is conjugated to the immunogenic carrier via a linker.

3. The composition for use according to claim 1 , wherein the tumor or cancer is a gastrointestinal tumor or cancer, or a gastrin-responsive cancer.

4. The composition for use according to claim 3, wherein the gastrointestinal tumor or cancer is a gastrin-dependent gastrointestinal tumor or cancer.

5. The composition for use according to claim 3, wherein the tumor or cancer is a pancreatic tumor or cancer.

6. The composition for use according to claim 3, wherein the gastrin-responsive cancer is gastrinoma, lung cancer, or thyroid cancer.

7. The composition for use according to claim 1 , wherein the tumor or cancer is a solid tumor or cancer of the gastrointestinal tract.

8. The composition for use according to claim 7, wherein the tumor or cancer is a pancreatic solid tumor or cancer.

9. 2. The composition for use according to claim 1, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin.

10. The composition for use according to claim 2, wherein the linker comprises ε-maleimidocaproic acid N-hydroxysuccinamide ester.

11. The composition for use according to claim 2, wherein the linker and the gastrin peptide are separated by an amino acid spacer.

12. The composition for use according to claim 11, wherein the amino acid spacer is 1 to 10 amino acids in length.

13. The composition for use according to claim 12, wherein the amino acid spacer is 7 amino acids in length.

14. The composition for use according to claim 1, wherein the composition for use further comprises an adjuvant.

15. The composition for use according to claim 14, wherein the adjuvant is an oil-based adjuvant.

16. 2. The composition for use according to claim 1, wherein the gastrin peptide comprises, consists essentially of, or consists of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO:1), EGPWLEEEE (SEQ ID NO:2), EGPWLEEEEEAY (SEQ ID NO:3), and EGPWLEEEEEAYGWMDF (SEQ ID NO:4).

17. 1. A composition for use in treating a tumor or cancer in a subject, comprising: (a) a first composition comprising, consisting essentially of, or consisting of a conjugate comprising, consisting essentially of, or consisting of a gastrin immunogen conjugated to an immunogenic carrier; and (b) a second composition comprising anti-tumor or anti-cancer T cells. A composition for use comprising:

18. 18. The composition for use according to claim 17, wherein the gastrin immunogen is conjugated to the immunogenic carrier via a linker.

19. 18. The composition for use of claim 17, wherein the anti-tumor or anti-cancer T cells comprise a chimeric antigen receptor (CAR) that binds to a tumor-associated or cancer-associated antigen present on the tumor or cancer.

20. 18. The composition for use according to claim 17, wherein the tumor or cancer is a gastrointestinal tumor or cancer.

21. 21. The composition for use according to claim 20, wherein the tumor or cancer is a gastrin-dependent gastrointestinal tumor or cancer.

22. 21. The composition for use according to claim 20, wherein the tumor or cancer is a pancreatic tumor or cancer.

23. 18. The composition for use according to claim 17, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin.

24. The composition for use according to claim 18, wherein the linker comprises ε-maleimidocaproic acid N-hydroxysuccinamide ester.

25. 20. The composition for use according to claim 18, wherein the linker and the gastrin peptide are separated by an amino acid spacer.

26. 26. The composition for use according to claim 25, wherein the amino acid spacer is 1 to 10 amino acids in length.

27. 26. The composition for use according to claim 25, wherein the amino acid spacer is 7 amino acids in length.

28. 18. The composition for use according to claim 17, wherein the composition for use further comprises an adjuvant.

29. 29. The composition for use according to claim 28, wherein the adjuvant is an oil-based adjuvant.

30. 18. The composition for use according to claim 17, wherein the gastrin peptide comprises, consists essentially of, or consists of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO:1), EGPWLEEEE (SEQ ID NO:2), EGPWLEEEEEAY (SEQ ID NO:3), and EGPWLEEEEEAYGWMDF (SEQ ID NO:4).

31. 20. The composition for use of claim 19, wherein the CAR binds to an antigen selected from the group consisting of claudin 18.2 antigen, glypican 3 antigen, mesothelin antigen, carcinoembryonic antigen (CEA), prostate stem cell antigen (PSCA), and CD70 antigen.

32. 1. A composition for use in sensitizing a solid tumor or cancer in a subject to chimeric antigen receptor-T (CAR-T) cell therapy, comprising: (a) a first composition comprising, consisting essentially of, or consisting of a conjugate comprising, consisting essentially of, or consisting of a gastrin immunogen conjugated to an immunogenic carrier; and (b) a second composition comprising, consisting essentially of, or consisting of a CAR-T cell that targets an antigen present in a solid tumor or cancer. A composition for use comprising:

33. 33. The composition for use of claim 32, wherein the gastrin immunogen is conjugated to the immunogenic carrier via a linker.

34. 33. The composition for use according to claim 32, wherein the solid tumor or cancer is a solid gastrointestinal tumor or cancer.

35. 35. The composition for use according to claim 34, wherein the solid tumor or cancer is a solid gastrin-dependent gastrointestinal tumor or cancer.

36. 35. The composition for use according to claim 34, wherein the solid tumor or cancer is a solid pancreatic tumor or cancer.

37. 33. The composition for use according to claim 32, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, keyhole limpet hemocyanin, and bovine serum albumin.

38. 34. The composition for use according to claim 33, wherein the linker comprises ε-maleimidocaproic acid N-hydroxysuccinamide ester.

39. 34. The composition for use according to claim 33, wherein the linker and the gastrin peptide are separated by an amino acid spacer.

40. 40. The composition for use according to claim 39, wherein the amino acid spacer is 1 to 10 amino acids in length.

41. 40. The composition for use according to claim 39, wherein the amino acid spacer is 7 amino acids in length.

42. 33. The composition for use according to claim 32, wherein the composition further comprises an adjuvant.

43. 43. The composition for use according to claim 42, wherein the adjuvant is an oil-based adjuvant.

44. 33. The composition for use of claim 32, wherein the gastrin peptide comprises, consists essentially of, or consists of an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO:1), EGPWLEEEE (SEQ ID NO:2), EGPWLEEEEEAY (SEQ ID NO:3), and EGPWLEEEEEAYGWMDF (SEQ ID NO:4).

45. 33. The composition for use of claim 32, further comprising one or more additional anti-tumor or anti-cancer therapeutic agents.

46. 46. ​​The composition for use of claim 45, wherein the one or more additional anti-tumor or anti-cancer therapeutic agents is an immune checkpoint inhibitor.

47. 47. The composition for use of claim 46, wherein the immune checkpoint inhibitor inhibits the biological activity of a target polypeptide selected from the group consisting of cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 receptor (PD-1), and programmed cell death 1 receptor ligand (PD-L1).

48. 47. The composition for use of claim 46, wherein the immune checkpoint inhibitor is selected from the group consisting of ipilimumab, tremelimumab, nivolumab, pidilizumab, pembrolizumab, AMP514, AUNP12, BMS-936559 / MDX-1105, atezolizumab, MPDL3280A, RG7446, RO5541267, MEDI4736, and avelumab.

49. 33. The composition for use of claim 32, formulated for administration at a dose selected from the group consisting of about 50 μg to 1000 μg, about 50 μg to about 500 μg, about 100 μg to about 1000 μg, about 200 μg to about 1000 μg, and about 250 μg to about 500 μg.